<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Inhaled steroids with and without regular formoterol for asthma: serious adverse events - Janjua, S - 2019 | Cochrane Library</title> <meta content="Inhaled steroids with and without regular formoterol for asthma: serious adverse events - Janjua, S - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006924.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Inhaled steroids with and without regular formoterol for asthma: serious adverse events - Janjua, S - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006924.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006924.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Inhaled steroids with and without regular formoterol for asthma: serious adverse events" name="citation_title"/> <meta content="Sadia Janjua" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="sjanjua@sgul.ac.uk" name="citation_author_email"/> <meta content="Stefanie Schmidt" name="citation_author"/> <meta content="UroEvidence@Deutsche Gesellschaft für Urologie" name="citation_author_institution"/> <meta content="Montse Ferrer" name="citation_author"/> <meta content="IMIM (Hospital del Mar Medical Research Institute)" name="citation_author_institution"/> <meta content="Christopher J Cates" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006924.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006924.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006924.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006924.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenal Cortex Hormones [*adverse effects, therapeutic use]; Adrenergic beta‐2 Receptor Agonists [administration &amp; dosage, *adverse effects]; Anti‐Asthmatic Agents [administration &amp; dosage, *adverse effects, therapeutic use]; Asthma [*drug therapy]; Drug Therapy, Combination; Formoterol Fumarate [*adverse effects, therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006924.pub4&amp;doi=10.1002/14651858.CD006924.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006924\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006924\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","ja","fa","ko"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006924.pub4",title:"Inhaled steroids with and without regular formoterol for asthma: serious adverse events",firstPublishedDate:"Sep 25, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006924.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006924.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006924.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006924.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006924.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006924.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006924.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006924.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006924.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006924.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4666 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006924.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/appendices#CD006924-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/table_n/CD006924StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/table_n/CD006924StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Inhaled steroids with and without regular formoterol for asthma: serious adverse events</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#CD006924-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sadia Janjua</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#CD006924-cr-0003">Stefanie Schmidt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#CD006924-cr-0004">Montse Ferrer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information#CD006924-cr-0005">Christopher J Cates</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information/en#CD006924-sec-0132">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006924.pub4">https://doi.org/10.1002/14651858.CD006924.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006924-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006924-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006924-abs-0012">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006924-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006924-abs-0001" lang="en"> <section id="CD006924-sec-0001"> <h3 class="title" id="CD006924-sec-0001">Background</h3> <p>Epidemiological evidence has suggested a link between beta<sub>2</sub>‐agonists and increases in asthma mortality. There has been much debate about whether regular (daily) long‐acting beta<sub>2</sub>‐agonists (LABA) are safe when used in combination with inhaled corticosteroids (ICS). This updated Cochrane Review includes results from two large trials that recruited 23,422 adolescents and adults mandated by the US Food and Drug Administration (FDA). </p> </section> <section id="CD006924-sec-0002"> <h3 class="title" id="CD006924-sec-0002">Objectives</h3> <p>To assess the risk of mortality and non‐fatal serious adverse events (SAEs) in trials that randomly assign participants with chronic asthma to regular formoterol and inhaled corticosteroids versus the same dose of inhaled corticosteroid alone. </p> </section> <section id="CD006924-sec-0003"> <h3 class="title" id="CD006924-sec-0003">Search methods</h3> <p>We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trial registers for unpublished trial data as well as FDA submissions in relation to formoterol. The date of the most recent search was February 2019. </p> </section> <section id="CD006924-sec-0004"> <h3 class="title" id="CD006924-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials (RCTs) with a parallel design involving adults, children, or both with asthma of any severity who received regular formoterol and ICS (separate or combined) treatment versus the same dose of ICS for at least 12 weeks. </p> </section> <section id="CD006924-sec-0005"> <h3 class="title" id="CD006924-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. We obtained unpublished data on mortality and SAEs from the sponsors of the studies. We assessed our confidence in the evidence using GRADE recommendations. The primary outcomes were all‐cause mortality and all‐cause non‐fatal serious adverse events. </p> </section> <section id="CD006924-sec-0006"> <h3 class="title" id="CD006924-sec-0006">Main results</h3> <p>We found 42 studies eligible for inclusion and included 39 studies in the analyses: 29 studies included 35,751 adults, and 10 studies included 4035 children and adolescents. Inhaled corticosteroids included beclomethasone (daily metered dosage 200 to 800 µg), budesonide (200 to 1600 µg), fluticasone (200 to 250 µg), and mometasone (200 to 800 µg). Formoterol metered dosage ranged from 12 to 48 µg daily. Fixed combination ICS was used in most of the studies. We judged the risk of selection bias, performance bias, and attrition bias as low, however most studies did not report independent assessment of causation of SAEs. </p> <p><b>Deaths</b> </p> <p>Seventeen of 18,645 adults taking formoterol and ICS and 13 of 17,106 adults taking regular ICS died of any cause. The pooled Peto odds ratio (OR) was 1.25 (95% confidence interval (CI) 0.61 to 2.56, moderate‐certainty evidence), which equated to one death occurring for every 1000 adults treated with ICS alone for 26 weeks; the corresponding risk amongst adults taking formoterol and ICS was also one death (95% CI 0 to 2 deaths). No deaths were reported in the trials on children and adolescents (4035 participants) (low‐certainty evidence). </p> <p>In terms of asthma‐related deaths, no children and adolescents died from asthma, but three of 12,777 adults in the formoterol and ICS treatment group died of asthma (both low‐certainty evidence). </p> <p><b>Non‐fatal serious adverse events</b> </p> <p>A total of 401 adults experienced a non‐fatal SAE of any cause on formoterol with ICS, compared to 369 adults who received regular ICS. The pooled Peto OR was 1.00 (95% CI 0.87 to 1.16, high‐certainty evidence, 29 studies, 35,751 adults). For every 1000 adults treated with ICS alone for 26 weeks, 22 adults had an SAE; the corresponding risk for those on formoterol and ICS was also 22 adults (95% CI 19 to 25). </p> <p>Thirty of 2491 children and adolescents experienced an SAE of any cause when receiving formoterol with ICS, compared to 13 of 1544 children and adolescents receiving ICS alone. The pooled Peto OR was 1.33 (95% CI 0.71 to 2.49, moderate‐certainty evidence, 10 studies, 4035 children and adolescents). For every 1000 children and adolescents treated with ICS alone for 12.5 weeks, 8 had an non‐fatal SAE; the corresponding risk amongst those on formoterol and ICS was 11 children and adolescents (95% CI 6 to 21). </p> <p><b>Asthma‐related serious adverse events</b> </p> <p>Ninety adults experienced an asthma‐related non‐fatal SAE with formoterol and ICS, compared to 102 with ICS alone. The pooled Peto OR was 0.86 (95% CI 0.64 to 1.14, moderate‐certainty evidence, 28 studies, 35,158 adults). For every 1000 adults treated with ICS alone for 26 weeks, 6 adults had an asthma‐related non‐fatal SAE; the corresponding risk for those on formoterol and ICS was 5 adults (95% CI 4 to 7). </p> <p>Amongst children and adolescents, 9 experienced an asthma‐related non‐fatal SAE with formoterol and ICS, compared to 5 on ICS alone. The pooled Peto OR was 1.18 (95% CI 0.40 to 3.51, very low‐certainty evidence, 10 studies, 4035 children and adolescents). For every 1000 children and adolescents treated with ICS alone for 12.5 weeks, 3 had an asthma‐related non‐fatal SAE; the corresponding risk on formoterol and ICS was 4 (95% CI 1 to 11). </p> </section> <section id="CD006924-sec-0007"> <h3 class="title" id="CD006924-sec-0007">Authors' conclusions</h3> <p>We did not find a difference in the risk of death (all‐cause or asthma‐related) in adults taking combined formoterol and ICS versus ICS alone (moderate‐ to low‐certainty evidence). No deaths were reported in children and adolescents. The risk of dying when taking either treatment was very low, but we cannot be certain if there is a difference in mortality when taking additional formoterol to ICS (low‐certainty evidence). </p> <p>We did not find a difference in the risk of non‐fatal SAEs of any cause in adults (high‐certainty evidence). A previous version of the review had shown a lower risk of asthma‐related SAEs in adults taking combined formoterol and ICS; however, inclusion of new studies no longer shows a difference between treatments (moderate‐certainty evidence). </p> <p>The reported number of children and adolescents with SAEs was small, so uncertainty remains in this age group. </p> <p>We included results from large studies mandated by the FDA. Clinical decisions and information provided to patients regarding regular use of formoterol and ICS need to take into account the balance between known symptomatic benefits of formoterol and ICS versus the remaining degree of uncertainty associated with its potential harmful effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006924-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006924-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006924-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006924-abs-0013">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006924-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006924-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006924-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006924-abs-0005" lang="en"> <h3>Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events </h3> <p><b>Review question</b> </p> <p>Is it safe to add regular formoterol to inhaled corticosteroid (ICS) for adults or children with asthma? </p> <p><b>Background</b> </p> <p>Asthma is a disease of the lungs. Symptoms include wheezing, breathlessness, and chest tightness. Two main features of asthma are underlying inflammation and bronchoconstriction (tightening of the muscles around small tubes in the lungs). The inflammation can be treated with daily steroid inhalers. The bronchoconstriction can be treated with a beta<sub>2</sub>‐agonist to relax the muscles. This opens up the airways and makes it easier to breathe. Beta<sub>2</sub>‐agonists can be used two ways: to provide relief from symptoms of chest tightness ('short‐acting beta<sub>2</sub>‐agonists') and to help prevent symptoms from occurring ('long‐acting beta<sub>2</sub>‐agonists', or LABAs). </p> <p>When asthma is not controlled by daily low‐dose ICS, many asthma guidelines recommend additional daily LABA, such as formoterol. We are confident that LABA improves lung function, symptoms, quality of life, and exacerbations. However, there is long‐standing controversy about how safe these drugs are for people with asthma. This is what we wanted to explore in this review by focusing on rare and serious harms. These are defined as events that are life‐threatening, require admission to hospital or prolongation of existing hospitalisation, or result in persistent or significant disability/incapacity or a birth defect. </p> <p><b>Key results</b> </p> <p>We analysed data from 29 studies in 35,751 adults and 10 studies in 4035 children aged up to 17 years. The participants in the studies had a range of asthma severity, with most having been previously treated with regular ICS (over a wide range of doses). There were too few children in the studies to allow us to be certain about the effects in children. </p> <p>Thirty deaths were reported in 35,751 adults. Seventeen of these deaths were reported in participants taking formoterol and ICS, and 13 deaths in participants who were taking ICS alone. Three deaths reported in adults taking formoterol and ICS were due to asthma, but there were no deaths due to asthma with ICS alone. No deaths were reported in children up to 17 years age. </p> <p>The number of people experiencing serious harms of any cause was similar in adults with and without formoterol. Although there was no difference in the risk of serious harms in adults with asthma taking regular formoterol in combination with ICS compared to ICS alone, we could not confidently exclude a reduced or increased risk of events compared to taking ICS alone. </p> <p><b>Quality of the evidence</b> </p> <p>We were moderately certain regarding the data in adults, but less certain about the effects of adding formoterol to ICS in children. Given the low number of deaths that occurred in the studies, we do not yet have enough information to be able to measure accurately the risk of adding formoterol to ICS on number of deaths. </p> <p>Almost all trials were sponsored by drug manufacturers.</p> <p>Other concerns were that the cause of serious adverse events (i.e. whether they were judged by the trialists to be asthma‐related or not) were not independently assessed, and it may have been possible to guess which treatment group the person experiencing the adverse event was from. Although the people in the trial did not know whether they had been given a dummy drug or the active treatment, formoterol has quite a large effect on symptoms. This meant that they might have been able to guess who was taking formoterol. It was not possible for us to tell whether this occurred or not, which is why we primarily look at the all‐cause events, which do not require assessment of cause. </p> <p><b>Conclusions</b> </p> <p>We are not able to state confidently that adding formoterol to ICS carries no risk of increasing the number of deaths in comparison with ICS alone. On the other hand, we found no conclusive evidence of an increase in serious harm. Three asthma‐related deaths occurred in a total of 12,777 adults treated with formoterol in combination with ICS. We found no conclusive evidence of risk of non‐fatal serious harms attributed to asthma when formoterol was combined with ICS in adults. </p> <p>This Plain language summary is current as of February 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006924-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-sec-0105">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-sec-0164">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006924-sec-0105"></div> <h3 class="title" id="CD006924-sec-0106">Implications for practice</h3> <section id="CD006924-sec-0106"> <p>In this update, we have included results from two large studies and now have data from a total of 35,751 adults and 4035 children and adolescents with asthma. Despite the increased precision of estimates as a result of the increased number of participants from the inclusion of new studies, we are still not able to reassure people with asthma that regular use of inhaled corticosteroids (ICS) with formoterol carries no increased risk of mortality compared with ICS alone in adults (moderate‐certainty evidence) or children and adolescents (low‐quality evidence). On the other hand, we found high‐certainty evidence of a similar rate of serious adverse events (SAEs) between therapies in adults. In addition, there were only three asthma‐related deaths from a total of 24,022 adults taking formoterol (low‐certainty evidence). </p> <p>In children and adolescents, the number of events was too small to determine whether the increase in all‐cause non‐fatal SAEs previously found in those taking regular formoterol alone was abolished by the additional use of ICS (moderate‐certainty evidence). However, the overall incidence of SAEs was lower in children and adolescents than adults. </p> <p>We were not able to identify studies to address the trade‐offs between mortality risks and quality of life of combined formoterol and ICS compared with ICS alone (see <a href="./appendices#CD006924-sec-0127">Appendix 5</a>). Clinical decisions and information provided to patients regarding regular use of formoterol must take into account the balance between known symptomatic benefits of formoterol and the degree of uncertainty associated with its potential harmful effects. </p> </section> <h3 class="title" id="CD006924-sec-0107">Implications for research</h3> <section id="CD006924-sec-0107"> <p>We investigated mortality and SAEs as outcomes of interest for those taking combined formoterol and ICS. For the next update of this review, a dose response analysis of combined formoterol and ICS (e.g. 12 µg versus 6 µg formoterol) and the frequency of associated SAEs will help to inform those prescribing inhalers. In addition, an analysis of outcomes after once‐daily versus twice‐daily combined formoterol and ICS would also be useful information for prescribers. </p> <p>Future research should clearly specify the number of participants with fatal and non‐fatal SAEs by treatment group and cause. We await publication of the separate results from adolescents included in the new trials. We identified two ongoing trials, one that has completed and an ongoing study recruiting over 2000 participants, which we will assess for eligibility when data become available (<a href="./references#CD006924-bbs2-0117" title="NCT02554786 . A multicenter randomised 52 week treatment double‐blind, triple dummy parallel group study to assess the efficacy and safety of QMF149 compared to mometasone furoate in patients with asthma. clinicaltrials.gov/ct2/show/NCT02554786 (first received 18 September 2015). ">NCT02554786</a>; <a href="./references#CD006924-bbs2-0118" title="NCT02741271 . Study of efficacy and long‐term safety of mometasone furoate in combination with formoterol fumarate versus mometasone furoate in children (5 to 11 years of age) with persistent asthma (MK‐0887A‐087) [A phase III, randomized, active‐controlled, parallel‐group clinical trial to study the efficacy and long‐term safety of mometasone furoate/formoterol fumarate (MF/F, MK‐0887A [SCH418131]), compared with mometasone furoate (MF, MK‐0887 [SCH032088]), in children with persistent asthma]. clinicaltrials.gov/ct2/show/NCT02741271 (first received 18 April 2016). ">NCT02741271</a>). As the trials included in this review were of mostly short duration, further trials should have a long enough duration to observe fatal and non‐fatal SAEs. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006924-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006924-sec-0029"></div> <div class="table" id="CD006924-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Regular formoterol and ICS compared to same‐dose ICS in adults with asthma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Formoterol and ICS compared to same‐dose ICS for chronic asthma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with chronic asthma<br/> <b>Intervention:</b> formoterol and ICS<br/> <b>Comparison:</b> same‐dose ICS </p> <p><b>Setting:</b> community; most were multicentre studies, of which 10 studies were conducted in the USA. Other multicentre studies were conducted in at least 2 to 27 countries including Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Chile, Finland, France, Germany, Hungary, Ireland, Luxembourg, Mexico, Norway, the Philippines, Poland, Spain, Thailand, and the UK. 2 single‐centre studies were conducted in Japan and Russia. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with same‐dose ICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with formoterol and ICS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.25<br/> (0.61 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,751<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause non‐fatal serious adverse events</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/> (19 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.87 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,751<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 3 more adults per 1000 experiencing an SAE compared to ICS treatment alone (i.e. 25 minus 22). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma mortality</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Pooled risk difference 0.0003 (−0.0007 to 0.0013)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,022<br/> (31 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 3 deaths in the LABA + ICS treatment arm for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related non‐fatal serious adverse events</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (4 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86<br/> (0.64 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,158<br/> (30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 1 more adults per 1000 experiencing an SAE compared to ICS treatment alone (i.e. 7 minus 6). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>ICS:</b> inhaled corticosteroids; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SAE:</b> serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the evidence for this outcome by 1 due to wide upper confidence interval of the absolute risk.<br/> <sup>2</sup>We downgraded the evidence for this outcome by 1 due to too few events in the ICS treatment arm.<br/> <sup>3</sup>We downgraded the evidence for this outcome by 1 due to lack of independent assessment of causation of SAEs. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006924-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Regular formoterol and ICS compared to same‐dose ICS in children and adolescents with asthma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Formoterol and ICS compared to same‐dose ICS for chronic asthma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adolescents with chronic asthma<br/> <b>Intervention:</b> formoterol and ICS<br/> <b>Comparison:</b> same‐dose ICS </p> <p><b>Setting:</b> community; all were multicentre studies, with 4 studies conducted in the USA and 1 study in the UK. Other studies were conducted in at least 7 countries including Argentina, Australia, Belgium, Brazil, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, India, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Switzerland, and Ukraine. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with same‐dose ICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with formoterol and ICS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled risk difference 0.0000 (95% CI −0.0034 to 0.0034)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause non‐fatal serious adverse events</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (6 to 21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.33<br/> (0.71 to 2.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 13 more children and adolescents per 1000 experiencing an SAE compared to ICS alone (i.e. 21 minus 8). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related mortality</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled risk difference 0.0000 (95% CI −0.0034 to 0.0034)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related non‐fatal serious adverse events</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (1 to 11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.18<br/> (0.40 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 8 more children and adolescents per 1000 experiencing an SAE compared to ICS alone (i.e. 11 minus 3). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>ICS:</b> inhaled corticosteroids; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SAE:</b> serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the evidence for this outcome by 2 due to no deaths and uncertainty of treatment.<br/> <sup>2</sup>We downgraded the evidence for this outcome by 1 due to wide confidence interval.<br/> <sup>3</sup>We downgraded the evidence for this outcome by 1 due to lack of independent assessment of causation of SAEs.<br/> <sup>4</sup>We downgraded the evidence for this outcome by 1 due to unexplained heterogeneity between trial results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006924-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-sec-0141">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD006924-sec-0030"></div> <section id="CD006924-sec-0031"> <h3 class="title" id="CD006924-sec-0031">Description of the condition</h3> <p>When asthma is not controlled by low‐dose inhaled corticosteroids (ICS) alone, many asthma guidelines recommend the use of additional long‐acting beta<sub>2</sub>‐agonists (LABA). Several Cochrane Reviews have addressed the efficacy of LABA in addition to ICS, <a href="./references#CD006924-bbs2-0130" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD005535; CD005535] ">Ducharme 2010b</a>; <a href="./references#CD006924-bbs2-0138" title="Ni ChroininM , GreenstoneI , LassersonTJ , DucharmeFM . Addition of long‐acting beta2‐agonists to inhaled steroids as first line therapy for persistent asthma in steroid‐naive adults and children. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005307.pub2] ">Ni Chroinin 2009a</a>, in comparison with placebo (<a href="./references#CD006924-bbs2-0145" title="WaltersEH , GibsonPG , LassersonTJ , WaltersJAE . Long‐acting beta2‐agonists for stable chronic asthma. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2] ">Walters 2007</a>), short‐acting beta<sub>2</sub>‐agonists (SABA) (<a href="./references#CD006924-bbs2-0144" title="WaltersEH , WaltersJAE , GibsonPW . Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD003901] ">Walters 2002</a>), and leukotriene‐receptor antagonists (LTRA) (<a href="./references#CD006924-bbs2-0131" title="DucharmeFM , LassersonTJ , CatesCJ . Addition to inhaled corticosteroids of long‐acting beta2‐agonists versus anti‐leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD003137.pub4] ">Ducharme 2011a</a>). The efficacy of LABA compared to increased doses of ICS has also been examined (<a href="./references#CD006924-bbs2-0129" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews2010, Issue 4. [DOI: 10.1002/14651858.CD005533.pub2] ">Ducharme 2010a</a>). The beneficial effects of LABA on lung function, symptoms, quality of life, and exacerbations requiring oral corticosteroids (OCS) have been demonstrated. </p> </section> <section id="CD006924-sec-0032"> <h3 class="title" id="CD006924-sec-0032">Description of the intervention</h3> <p>Two LABAs are currently available for the treatment of asthma: salmeterol and formoterol (also known as eformoterol). These two drugs have shown differences in speed of onset and receptor activity and are used in different ways: salmeterol has a slower onset of action than salbutamol (<a href="./references#CD006924-bbs2-0120" title="BeachJR , YoungCL , StentonSC , AveryAJ , WaltersEH , HendrickDJ . A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine‐induced bronchoconstriction. Pulmonary Pharmacology1992;5(2):133‐5. ">Beach 1992</a>), and is therefore unsuitable for use as a reliever, whereas formoterol in combination with ICS can be used for maintenance and relief of symptoms (MART). 'The Fenoterol Story' is a reminder that not all beta<sub>2</sub>‐agonists may carry the same risks (<a href="./references#CD006924-bbs2-0139" title="PearceN . Adverse Reactions: The Fenoterol Story. 1st Edition. Auckland: Auckland University Press, 2007. [9781869403744] ">Pearce 2007</a>), so in view of the potential differences in adverse effects between salmeterol and formoterol, we have considered the two drugs separately. </p> </section> <section id="CD006924-sec-0033"> <h3 class="title" id="CD006924-sec-0033">How the intervention might work</h3> <p>Much debate has focused on the interaction between ICS and LABA in relation to serious adverse events (SAEs) since the publication of <a href="./references#CD006924-bbs2-0142" title="NelsonHS , WeissST , BleeckerER , YanceySW , DorinskyPM , the SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest2006;129:15‐26. ">SMART 2006</a>. This study did not randomly assign participants to ICS, nevertheless a subgroup analysis of the results was carried out on the basis of ICS use at baseline. It is tempting to find reassurance from the fact that no statistically significant increase in asthma‐related mortality was observed in the subgroup using ICS, but this is not the correct way to test for interaction (<a href="./references#CD006924-bbs2-0119" title="AltmanDG , BlandJM . Statistics Notes: Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. ">Altman 2003</a>), and no assessment was carried out during the trial in relation to the actual use of ICS during the course of the study. </p> <p>Concern remains that the symptomatic benefit derived from treatment with LABAs might lead to underestimation of attack severity in acute asthma, and could lead to an increase in asthma‐related deaths. Furthermore, regular treatment with beta<sub>2</sub>‐agonists can lead to tolerance of their bronchodilator effects, and this phenomenon might be more marked with longer‐acting as opposed to shorter‐acting compounds (<a href="./references#CD006924-bbs2-0136" title="LipworthBJ . Airway sub‐sensitivity with long‐acting beta 2‐agonists: is there cause for concern?. Drug Safety1997;16(5):295‐308. ">Lipworth 1997</a>). A number of molecular mechanisms have been proposed to explain the possible detrimental effects for people taking beta<sub>2</sub>‐agonists long term, including receptor down‐regulation and desensitisation (<a href="./references#CD006924-bbs2-0132" title="GiembyczMA , NewtonR . Beyond the dogma: novel β2‐adrenoceptor signalling in the airways. European Respiratory Journal2006;27(6):1286‐306. ">Giembycz 2006</a>) </p> </section> <section id="CD006924-sec-0034"> <h3 class="title" id="CD006924-sec-0034">Why it is important to do this review</h3> <p>There has been a long‐standing controversy over the regular use of beta<sub>2</sub>‐agonists in asthma, which is ongoing. <a href="./references#CD006924-bbs2-0140" title="SearsM , ReaH , RothwellR , O'DonnellT , HolstP , GilliesA , et al. Asthma mortality: comparison between New Zealand and England. British Medical Journal1986;293(6558):1342‐5. ">Sears 1986</a> suggested that excessive use of SABA might have contributed directly or indirectly to an increase in asthma deaths in New Zealand between 1960 and 1980. The authors comment that "most deaths were associated with poor assessment, underestimation of severity and inappropriate treatment (over‐reliance on bronchodilators and under‐use of systemic corticosteroids), and delays in obtaining help". </p> <p>Counfounding by severity has been shown by <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> in data from the RELIEF study, where the rate of asthma‐related SAEs was significantly higher in both arms of the study amongst participants taking ICS in comparison with those not taking ICS. This is a serious threat to any conclusions drawn from observational data when the interaction between ICS and formoterol is assessed. Consequently, there is a need to systematically review all available data from controlled trials that randomly assigned participants to regular formoterol in combination with ICS, and to consider all SAEs (fatal and non‐fatal), whether or not these are deemed by the investigators to be related to trial medication. </p> <p>Two systematic reviews have addressed the impact of LABA on all‐cause mortality and SAEs. <a href="./references#CD006924-bbs2-0122" title="CatesCJ , CatesMJ . Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006922.pub4] ">Cates 2008</a> evaluated salmeterol, and <a href="./references#CD006924-bbs2-0123" title="CatesCJ , CatesMJ , LassersonTJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3; CD006923] ">Cates 2012</a> evaluated formoterol. Both reviews considered LABA that were randomly assigned without additional ICS and described increased risks of non‐fatal SAEs. </p> <p>A review comparing regular salmeterol randomly assigned in combination with ICS (in a single inhaler or in separate inhalers) versus ICS alone has recently been updated (<a href="./references#CD006924-bbs2-0125" title="CatesCJ , SchmidtS , FerrerM , SayerB , WatersonS . Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cochrane Database of Systematic Reviews2018, Issue 12. [DOI: 10.1002/14651858.CD006922.pub4] ">Cates 2018</a>), and an overview of the safety of regular formoterol or salmeterol in children has been published (<a href="./references#CD006924-bbs2-0124" title="CatesCJ , OleszczukM , StovoldE , WielandLS . Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD010005.pub2] ">Cates 2012a</a>). </p> <p>The focus of this review is on regular formoterol randomly assigned in combination with ICS (in a single inhaler or in separate inhalers) compared with ICS alone. Because of the difficulty involved in deciding whether adverse events are asthma‐related, this review focused on studies that captured mortality and SAEs and records both all‐cause outcomes and those considered by trial investigators to be asthma‐related events. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006924-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-sec-0146">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006924-sec-0035"></div> <p>To assess the risks of mortality and non‐fatal SAEs in trials that randomly assign participants with chronic asthma to regular formoterol and inhaled corticosteroid versus the same dose of inhaled corticosteroid alone. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006924-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-sec-0147">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006924-sec-0036"></div> <section id="CD006924-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006924-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included parallel‐design randomised controlled trials (RCTs), with or without blinding.</p> </section> <section id="CD006924-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included participants with a clinical diagnosis of asthma of any age group, unrestricted by disease severity or previous or current treatment. We excluded studies on acute asthma and exercise‐induced bronchospasm. </p> </section> <section id="CD006924-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared ICS and formoterol with ICS alone. We included studies where the treatments were taken regularly once or twice daily for a period of ≥ 12 weeks at any dose and delivered by any single or separate devices (i.e. chlorofluorocarbon metred‐dose inhaler (CFC‐MDI), hydrofluoroalkane metred‐dose inhaler (HFA‐MDI), or dry powder inhaler (DPI)). We included studies where the comparison groups took the same dose and type of inhaled corticosteroid. Co‐intervention with leukotriene‐receptor antagonists (LTRA), cromones, or theophylline was allowed as long as they were not part of the randomly assigned intervention and were therefore not systematically different between groups. </p> <p>We excluded studies that randomly assigned participants to formoterol and ICS for intermittent use as a reliever or studies that compared different doses of formoterol or different delivery devices or propellants without a placebo arm. We also excluded studies in which ICS were used in all participants as background treatment (rather than as a randomised intervention). </p> </section> <section id="CD006924-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD006924-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006924-list-0001"> <li> <p>All‐cause mortality.</p> </li> <li> <p>All‐cause non‐fatal SAEs.</p> </li> </ul> </p> </section> <section id="CD006924-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006924-list-0002"> <li> <p>Asthma‐related mortality.</p> </li> <li> <p>Asthma‐related non‐fatal SAEs.</p> </li> <li> <p>Respiratory‐related mortality.</p> </li> <li> <p>Respiratory‐related non‐fatal SAEs.</p> </li> <li> <p>Cardiovascular‐related mortality.</p> </li> <li> <p>Cardiovascular‐related non‐fatal SAEs.</p> </li> <li> <p>Asthma‐related non‐fatal life‐threatening events (intubation or admission to intensive care). </p> </li> <li> <p>Respiratory‐related non‐fatal life‐threatening events (intubation or admission to intensive care). </p> </li> </ul> </p> <p>We did not subgroup outcomes according to whether the trial investigators considered them to be related to trial medication. </p> <p>For the definition of a non‐fatal SAE, see <a href="./appendices#CD006924-sec-0111">Appendix 1</a>. </p> </section> </section> </section> <section id="CD006924-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006924-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The previously published version included searches up to August 2012 (see <a href="./appendices#CD006924-sec-0112">Appendix 2</a>). We updated the search for this version from 2011 to 18 February 2019. </p> <p>We identified studies from the Cochrane Airways Trials Register (<a href="./references#CD006924-bbs2-0127" title="Cochrane Airways Trials Register. airways.cochrane.org/trials‐register (accessed 8 April 2019). ">Cochrane Airways 2019</a>), which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from several sources: </p> <p> <ul id="CD006924-list-0003"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies; </p> </li> <li> <p>weekly searches of MEDLINE Ovid SP 2011 to 18 February 2019;</p> </li> <li> <p>weekly searches of Embase Ovid SP 2011 to 18 February 2019;</p> </li> <li> <p>monthly searches of PsycINFO Ovid SP 2011 to 18 February 2019;</p> </li> <li> <p>monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature) 2011 to 18 February 2019; </p> </li> <li> <p>monthly searches of AMED EBSCO (Allied and Complementary Medicine) all years to date;</p> </li> <li> <p>handsearches of the proceedings of major respiratory conferences.</p> </li> </ul> </p> <p>Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings, are provided in <a href="./appendices#CD006924-sec-0113">Appendix 3</a>. The search strategy used to identify studies for this review is presented in <a href="./appendices#CD006924-sec-0119">Appendix 4</a>. </p> <p>We also searched the following trials registries:</p> <p> <ul id="CD006924-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>We searched the Cochrane Airways Trials Register and additional sources to 18 February 2019, with no restriction on language or type of publication. </p> </section> <section id="CD006924-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We checked websites of clinical trial registers for unpublished trial data. We searched relevant manufacturers' websites for study information. We also checked US Food and Drug Administration (FDA) submissions in relation to formoterol. We searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) on 8 April 2019. </p> </section> </section> <section id="CD006924-sec-0047"> <h3 class="title" id="CD006924-sec-0047">Data collection and analysis</h3> <section id="CD006924-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SJ, CJC) independently screened the titles and abstracts of the search results and coded them as 'retrieved' (eligible or potentially eligible/unclear) or 'did not retrieve'. We retrieved the full‐text study reports of all potentially eligible studies, and two review authors (SJ, CJC) independently screened them for inclusion, recording the reasons for exclusion of ineligible studies. Any disagreements were resolved through discussion. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (<a href="https://archie.cochrane.org/sections/documents/view?document=z1902041636315949324365518096152%26format=REVMAN#REF-Moher-2009" target="_blank">Moher 2009</a>). </p> </section> <section id="CD006924-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>For the current update, we used Covidence to extract data and assess risk of bias for each included study (<a href="./references#CD006924-bbs2-0128" title="Veritas Health Innovation. Covidence systematic review software. Melbourne: Veritas Health Innovation, accessed February 2018. ">Covidence systematic review software</a>). </p> <p>We extracted data on characteristics of included studies (methods, participants, interventions, outcomes) and results of the included studies. We contacted sponsors of the included studies for unpublished adverse event data and searched the sponsor's website for further details of adverse events. All‐cause SAEs (fatal and non‐fatal) were recorded, and in view of the difficulty involved in deciding whether events were asthma‐related, details of the cause of death and of SAEs were noted when available. The definition of 'serious adverse events' used in a particular trial was recorded, and further information was sought if this was not clear (particularly in relation to hospital admissions and SAEs). </p> <p> <ul id="CD006924-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: N, mean age, severity of condition, baseline lung function, inclusion criteria and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for studies and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (SJ, CJC) independently extracted outcome data from the included studies. We noted in the 'Characteristics of included studies' table if outcome data were not reported in a useable way. Any disagreements were resolved by consensus. One review author (SJ) transferred data into the Review Manager 5 file (<a href="https://archie.cochrane.org/sections/documents/view?document=z1902041636315949324365518096152%26format=REVMAN#REF-RevMan-2014" target="_blank">RevMan 2014</a>). We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (CJC) spot‐checked study characteristics for accuracy against the study report. </p> </section> <section id="CD006924-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SJ, CJC) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (with assistance from Susan Hansen for the original version of the review) (<a href="./references#CD006924-bbs2-0133" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).. In: The Cochrane Collaboration, editor(s). Available from http://handbook.cochrane.org.. Wiley, 2011. ">Higgins 2011</a>). Any disagreements were resolved by discussion. We assessed risk of bias according to the following domains: </p> <p> <ul id="CD006924-list-0006"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting (we considered studies to be at high risk of bias if independent assessment of causation of SAEs was lacking); </p> </li> <li> <p>other bias.</p> </li> </ul> </p> <p>We judged each potential source of bias as high, low, or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary. Where information on risk of bias related to unpublished data or correspondence with trialists, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD006924-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>The outcomes used in this review were dichotomous. We recorded the number of participants with one or more outcome events by allocated treated group. </p> <p>We undertook meta‐analyses only where this was meaningful, that is if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>Where multiple trial arms were reported in a single study, we included only the relevant arms. If two comparisons (e.g. low‐dose ICS/formoterol versus ICS and high‐dose ICS/formoterol versus ICS) were combined in the same meta‐analysis, we combined the active arms or halved the control group in order to avoid double‐counting. </p> <p>We used intention‐to‐treat or 'full analysis set' analyses where they were reported (i.e. analyses where data had been imputed for participants who were randomly assigned but did not complete the study) instead of completer or per‐protocol analyses. </p> </section> <section id="CD006924-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We confined our analysis to participants with one or more SAEs, rather than focusing on the number of events that occurred (as the latter is not independent when one participant experiences multiple events, and a single SAE may be recorded under several different categories). </p> </section> <section id="CD006924-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified as an abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we took this into consideration in the GRADE assessment for affected outcomes. </p> </section> <section id="CD006924-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic to measure heterogeneity amongst the studies in each analysis employing the following criteria (<a href="./references#CD006924-bbs2-0133" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).. In: The Cochrane Collaboration, editor(s). Available from http://handbook.cochrane.org.. Wiley, 2011. ">Higgins 2011</a>): </p> <p> <ul id="CD006924-list-0007"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>In the case of substantial heterogeneity, we reported it and explored the possible causes by prespecified subgroup analysis. </p> </section> <section id="CD006924-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We obtained full data on all‐cause mortality and SAEs. Where data for asthma‐related SAEs were not reported, we judged studies as 'high risk', and 'unclear risk' if the information provided by the authors or sponsors was insufficient. Upon pooling of more than 10 studies, we created and examined a funnel plot to explore possible small‐study and publication biases. </p> </section> <section id="CD006924-sec-0056"> <h4 class="title">Data synthesis</h4> <p>The outcomes of this review were dichotomous, and we recorded the numbers of participants with at least one outcome event by allocated treated group. We calculated Peto odds ratios (ORs) and risk differences (RDs). The Peto OR is advantageous when events are rare, as no adjustment for zero cells is required (<a href="./references#CD006924-bbs2-0121" title="BradburnMJ , DeeksJJ , BerlinJA , Russell LocalioA . Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine2007;26(1):53‐77. ">Bradburn 2007</a>). In view of the low number of events and the high proportion of zero cells, we considered this specific property to be more important than potential problems with unbalanced treatment arms and large effect sizes associated with this method. The primary analysis of results for SAE outcomes was conducted in Review Manager 5 using the Peto method, and the Mantel‐Haenszel method was used as a sensitivity analysis. We used a random‐effects model and performed a sensitivity analysis with a fixed‐effect model if required. </p> </section> <section id="CD006924-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We undertook subgroup analyses on the basis of participant age (adults versus children) and the dose of formoterol used (usual dose versus high dose). We also carried out subgroup analyses comparing the different types of ICS now included in this review, and had sufficient data to divide budesonide into high dose (800 µg daily) and moderate dose (400 µg or less daily) in adults. We made subgroup comparisons using tests for interaction (<a href="./references#CD006924-bbs2-0119" title="AltmanDG , BlandJM . Statistics Notes: Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. ">Altman 2003</a>). We were unable to carry out planned subgroups based on asthma severity (see <a href="#CD006924-sec-0136">Differences between protocol and review</a>). </p> </section> <section id="CD006924-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to assess the impact of the method used to combine study events (RD, Peto OR, and Mantel‐Haenszel OR). We included the degree of bias protection as part of the sensitivity analysis (with an emphasis on independent outcome assessment for the asthma‐related events). We also included a post hoc sensitivity analysis excluding the results from studies in which formoterol and ICS were administered in separate inhalers. </p> <section id="CD006924-sec-0059"> <h5 class="title">'Summary of findings' tables</h5> <p>We assessed the certainty of the evidence for all‐cause mortality, all‐cause non‐fatal SAEs, and asthma‐related SAEs. Assessments were conducted according to recommendations put forth by the <a href="http://www.gradeworkinggroup.org/" target="_blank">GRADE Working Group</a> and are presented in <a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a> for adults <a href="./full#CD006924-tbl-0002">summary of findings Table 2</a> for children and adolescents for key outcomes (all‐cause mortality, asthma‐related mortality, all‐cause non‐fatal SAEs, and asthma‐related SAEs). </p> <p>We created our 'Summary of findings' tables using the following outcomes: all‐cause mortality, all‐cause non‐fatal SAEs, asthma‐related mortality, and asthma‐related non‐fatal SAEs. We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence relating to the studies that contributed data for the prespecified outcomes. We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://archie.cochrane.org/sections/documents/view?document=z1902041636315949324365518096152%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>), employing GRADEpro GDT software (<a href="https://archie.cochrane.org/sections/documents/view?document=z1902041636315949324365518096152%26format=REVMAN#REF-GRADEpro-GDT" target="_blank">GRADEpro GDT</a>). We justified all decisions to downgrade the certainty of evidence using footnotes and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006924-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006924-sec-0060"></div> <section id="CD006924-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD006924-sec-0062"> <h4 class="title">Results of the search</h4> <p>We included a total of 27 trials from the previous version of this review (21 trials included in the 2008 update, and a further six trials from the 2012 update search) (<a href="./references#CD006924-bbs2-0123" title="CatesCJ , CatesMJ , LassersonTJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3; CD006923] ">Cates 2012</a>). The current update covers the period from 2011 to 2019. We identified a further 454 abstracts, of which 48 were considered as potentially relevant to this review. Full‐text assessment led to the inclusion of 33 studies that met the inclusion criteria. Fifteen of the 33 studies were identified as new trials (<a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a>; <a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a>; <a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a>; <a href="./references#CD006924-bbs2-0016" title="NathanRA , D'UrzoA , BlazhkoV , KaiserK . Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine2012;12:67. [NCT00393991] ">Nathan 2012</a>; <a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a>; <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a>; <a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a>; <a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>; <a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>; <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>). The remaining 18 studies included 16 additional references for the 15 new trials (13 conference abstracts, two ClinicalTrials.gov references, and one further publication for <a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a>), and two ongoing trials (<a href="./references#CD006924-bbs1-0003" title="">Ongoing studies</a>), </p> <p>Twelve of the 15 trials included adults taking regular formoterol in combination with either beclomethasone, budesonide, fluticasone, or mometasone (<a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a>; <a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a>; <a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a>; <a href="./references#CD006924-bbs2-0016" title="NathanRA , D'UrzoA , BlazhkoV , KaiserK . Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine2012;12:67. [NCT00393991] ">Nathan 2012</a>; <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a>; <a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>; <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>). The remaining three trials of formoterol in combination with either budesonide or fluticasone involved children (<a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a>; <a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a>; <a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a>). </p> <p>Three of the trials in adults did not report outcome data, and although they met the inclusion criteria, they were not included in the analyses (<a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>). </p> <p>With the studies from the previous updates and current update, we have included a total of 42 trials (<a href="./references#CD006924-sec-0138" title="">Characteristics of included studies</a>), of which 39 are included in the analyses (<a href="#CD006924-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006924-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD006924-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> </section> <section id="CD006924-sec-0063"> <h4 class="title">Included studies</h4> <p>The 42 studies included in this review are described in detail in <a href="./references#CD006924-sec-0138" title="">Characteristics of included studies</a>, and a summary of the daily metered dose of beclomethasone, budesonide, fluticasone, or mometasone in addition to formoterol used in each trial is provided in <a href="#CD006924-tbl-0003">Table 1</a> for adults and <a href="#CD006924-tbl-0004">Table 2</a> for children. To avoid confusion, all delivered doses in these tables have been converted to an equivalent metered dose (so budesonide/formoterol (Symbicort) 320/9 µg is a delivered dose that is equivalent to a metered dose of budesonide 400 µg and formoterol 12 µg). </p> <div class="table" id="CD006924-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adults daily metred dose and delivery of beclomethasone, budesonide, fluticasone, or mometasone with formoterol</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on formoterol/ICS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on ICS alone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose (µg), (steroid)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose formoterol (µg)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Once daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Twice daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combined inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Separate inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DPI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>pMDI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (weeks)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0003" title="ChuchalinA , StahlE , SvenssonK , OvcharenkoS , GoriachkinaL , SidorenkoI , et al. Formoterol (Oxis(r)) Turbuhaler(r) plus budesonide Turbuhaler(r) and budesonide alone improve health‐related quality of life vs non‐steroid therapy in mild to moderate asthma in Russia [Abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN . Formoterol Oxis® Turbuhaler® plus budesonide Turbuhaler® is more effective than current non‐steroid therapy and budesonide alone in mild to moderate asthma in Russia. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN , EPOCH Study Group. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non‐corticosteroid therapy in Russia. International Journal of Clinical Practice2002; Vol. 56, issue 1:15‐20. ChuchalinAG , SvenssonK , StahlE , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , et al. A health‐related quality‐of‐life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration2002;69(5):427‐33. ">Chuchalin 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0004" title="AstraZenecaSD‐039‐0716 . Efficacy of Symbicort versus its mono components ‐ SPRUCE 80/4.5 [A 12 week randomised, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (160/4.5mcg) versus its mono‐products (budesonide and formoterol) in children (at least 6 years of age) and adults with Asthma‐SPRUCE 80/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=970 (first received 1 August 2002). CorrenJ , KorenblatPE , MillerCJ , O'BrienCD , MezzanotteWS . Twelve‐week, randomised, placebo‐controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered‐dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics2007; Vol. 29, issue 5:823‐43. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in adults with mild to moderate persistent asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:928. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . The effect of budesonide and formoterol in one pressurized metered‐dose inhaler on patient‐reported outcomes in adults with mild‐to‐moderate persistent asthma. Current Medical Research and Opinion2008;24(3):879‐94. ">Corren 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0006" title="AstraZenecaD58960001 . Gemini Symbicort pMDI [A randomized, double‐blind, active‐controlled, parallel‐group, single dummy, multicenter, 12 week study to assess the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations once‐daily (qd) compared to SYMBICORT pMDI 80/4.5 μg × 2 actuations qd, SYMBICORT pMDI80/4.5 μg × 2 actuations twice‐daily (bid) and to budesonide pMDI 160 μg × 2 actuations qd in asthmatic subjects 12 years of age and older]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1581 (first received 20 October 2003). KerwinEM , OppenheimerJJ , LaForceC , MillerCJ , O'DowdL , GoldmanM . Effects on pulmonary function of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152‐3. LaForceC , KerwinEM , OppenheimerJJ , MillerCJ , VervaetP , O'DowdL , et al. Safety of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S153. OppenheimerJJ , KerwinEM , LaForceC , MillerCJ , O'DowdL , GoldmanM . Asthma control with once‐daily (qd) budesonide/formoterol pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. ">D5896C00001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BEC)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1600 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0009" title="AstraZenecaSD‐039‐0665 . Symbicort low dose once daily in mild to moderate asthmatic patients. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1013 (first received 1 November 1999). KunaP , ChuchalinA , RingdalN , De laPadillaEA , BlackP , LindqvistA , et al. Low‐dose single‐inhaler budesonide/formoterol administered once daily is effective in mild‐persistent asthma. European Respiratory Journal2001;18(Suppl 33):158s. KunaP , CreemersJ , VondraV , BlackPN , LindqvistA , NihlenU , et al. Once‐daily dosing with budesonide/formoterol compared with twice‐daily budesonide/formoterol and once‐daily budesonide in adults with mild to moderate asthma. Respiratory Medicine2006; Vol. 100, issue 12:2151‐9. ">Kuna 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0011" title="MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10µg twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids. World Allergy Organization Journal2012;5 (Suppl 2):S80‐1. MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:1203. MeltzerE , NolteH , LaforceC . Low‐dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology2009;A66:P92. MeltzerEO , KunaP , NolteH , NayakAS , LaforceC . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal2012;39(2):279‐89. [1399‐3003: (Electronic)] MeltzerEO , NolteH , LaForceC . Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice‐daily administered via a pressurized metered‐dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A5661. ">Meltzer 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0012" title="AstraZeneca . A randomised, double‐blind, parallel‐group, multi centre phase‐III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 160/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 200 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 160/4.5 mcg 2 inhalations b.i.d., delivered dose) in adolescents and adults with asthma. www.astrazenecaclinicaltrials.com/search/?itemId=8574676 (first received 26 November 2008). MoriceAH , HochmuthL , PutermanA , ArthedenL , BeckmanO . Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy and Clinical Immunology2005; Vol. 115, issue 2 Suppl:S3. MoriceAH , PetersonS , BeckmanO , OsmanlievD . Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice2007;61(11):1874‐83. [1368‐5031: (Print)] ">Morice 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>462</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0016" title="NathanRA , D'UrzoA , BlazhkoV , KaiserK . Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine2012;12:67. [NCT00393991] ">Nathan 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0018" title="AstraZenecaSD‐039‐0717 . A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐controlled trial of SYMBICORT® (160/4.5 mcg) versus its mono‐products (budesonide and formoterol) in adolescents (&gt; 12 years of age) and adults with asthma, international. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=969 (first received 1 July 2002). BakerJ , MartinP , ParasuramanB . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in patients with asthma. Chest2007;132(4):509b. NoonanM , RosenwasserLJ , MartinP , O'BrienCD , O'DowdL . Efficacy and safety of budesonide and formoterol in one pressurised metered‐dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs2006;66(17):2235‐54. NoonanMJ , EidNS , UryniakT , O'BrienCD . Safety of once daily (qd) budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children and adolescents with asthma previously stable on twice daily (bid) BUD/FM pMDI [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:Abstract 711 [#K71]. RosenwasserLJ , NoonanMJ , MartinP , O'DowdL , O'BrienCD . Safety of budesonide and formoterol administered via one pressurized metered dose inhaler (budesonide/formoterol pMDI) in patients (&gt;12 years) with moderate to severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S5. Abstract 17. ">Noonan 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0025" title="AstraZenecaSD‐039‐0728 . Titratable dosing in moderate to severe asthmatics [A 52‐week, randomized, double‐blind, single‐dummy, parallel‐group, multicenter Phase III study comparing the long‐term safety of SYMBICORT® pMDI 160/4.5 mcg × 4 actuations twice daily to SYMBICORT® pMDI 160/4.5 mcg × 2 actuations twice daily and budesonide HFA pMDI 160 mcg × 4 actuations twice daily in adult and adolescent subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=964 (first received 1 August 2003). LawranceR , AmbroseH , GoldmanM . Effect of gly16arg beta2‐adrenergic receptor variation on the long‐term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered‐dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #420. O'BrienCD , PetersSP , PrennerBM , MartinP . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L57. O'BrienCD , PetersSP , PrennerBM , MartinP . Resource use with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L58. PetersSP , PrennerBM , MartinP , O'BrienCD . Long‐term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered‐dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #K5. PetersSP , PrennerBM , MezzanotteWS , MartinP , O'BrienCD . Long‐term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered‐dose inhaler in asthma. Allergy and Asthma Proceedings2008;29:1‐18. PrennerBM , PetersSP , MartinP , O'BrienCD . Long‐term control of asthma symptoms with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L67. PrennerBM , PetersSP , MartinP , O'BrienCD . Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/FM) pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:#L66. TashkinD , ChippsB , BrownR , UryniakT , TrudoF . Responder analysis evaluating the long‐term treatment of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in patients with moderate to severe asthma with versus without fixed airflow obstruction (FAO) [Abstract]. Chest2013;144:4. [DOI: 79A] ">Peters 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>443</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1600 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1645</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1646</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0029" title="PriceD , DutchmanD , MawsonA , BodaliaB , DugganS , ToddP . Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax2002;57(9):791‐8. [0040‐6376: (Print)] PriceMJ , BriggsAH . Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics2002;20(3):183‐94. PriceMJ , SondhiS , YanS , NythA , HouseK . Salmeterol/fluticasone propionate combination inhaler is more cost effective than fluticasone propionate in patients with asthma. European Respiratory Society 9th Annual Congress; 1999 Oct 9‐13; Madrid. 1999:#2459. ">Price 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0035" title="AstraZenecaSD‐039‐0726 . Efficacy of Symbicort pMDI administered once daily in adolescents and adults during 12 weeks ‐ STEM [A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma ‐ STEM]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=965 (first received 1 April 2003). ">SD‐039‐0726</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0036" title="AstraZenecaD589BL00003 . Phase4/Symbicort® versus Pulmicort Flexhaler® in African Americans (Titan) [A 12‐week, randomized, double‐blind, double‐dummy, multi‐center, phase IV study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations twice daily versus budesonide inhalation powder DPI 180 μg × 2 inhalations twice daily, in adult and adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1614 (first received 1 June 2008). [D589BL00003] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Budesonide/formoterol pressurized metered‐dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. Journal of Asthma2012;49(1):70‐7. [1532‐4303: (Electronic)] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Effect of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(Suppl):5. SpectorSL , O'BrienCD , UryniakT , MartinUJ . Safety and tolerability of a budesonide/formoterol (BUD/FM) pressurized metered‐dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Chest2010;138(4):705A. ">Spector 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0039" title="NCT00381485 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED) [A 12‐week efficacy and safety study of two doses of mometasone furoate/formoterol combination formulation compared with mometasone furoate monotherapy, in persistent asthmatics previously treated with high‐dose inhaled glucocorticosteroids]. clinicaltrials.gov/ct2/show/NCT00381485 (first received 27 September 2006). [NCT00381485] NolteH , WhiteM , WeinsteinSF , NathanRA , GatesD , MeltzerEO . Evaluation of diary data on asthma control factors managed with combined mometasone furoate and formoterol fumarate in patients with severe asthma. Respirology2012;17 (Suppl 2):1‐16. WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB196. [0091‐6749] WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. European Respiratory Society https://www.ers‐education.org/home/browse‐all‐content.aspx?idParent=861112010;36(Suppl 54):5482. WeinsteinS , MurphyK , NolteH . Efficacy and safety of two doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. World Allergy Organization. 2012:S79‐80. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered‐dose inhaler device. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5411. WeinsteinS , WhiteM , CorrenJ , NolteH . Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna. 2009:E280. WeinsteinSF , CorrenJ , MurphyK , NolteH , WhiteM . Twelve‐week efficacy and safety study of mometasone furoate/formoterol 200/10 [micro]g and 400/10 [micro]g combination treatments in patients with persistent asthma previously receiving high‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):280‐9. WeinsteinSF , WhiteM , CorrenJ , NolteH . Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered‐dose inhaler (MDI), in severe asthma patients previously treated with high‐dose inhaled corticosteroids (ICS). American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:J53. ">Weinstein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5868</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5861</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 or 800 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0041" title="NCT00419757 . An efficacy study comparing SYMBICORT® pressurised metered dose Iinhaler (pMDI) with budesonide hydrofluoroalkanes (HFA) pMDI, in hispanic subjects with ICS dependent asthma [A 12‐week, randomised, double blind, active‐controlled, multi‐centre, phase IIIB study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily versus budesonide HFA pMDI 160 mg x 2 actuations twice daily, in adult/adolescent (&gt; 12 Yrs) Hispanic subjects with asthma]. clinicaltrials.gov/ct2/show/NCT00419757 (first received 9 January 2007). [NCT00419757] ZangrilliJ , MansfieldLE , UryniakT , O'BrienCD . Efficacy of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide pressurized metered‐dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Annals of Allergy, Asthma and Immunology2011;107:258‐65. ">Zangrilli 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: BEC: beclomethasone; BUD: budesonide; DPI: dry powder inhaler; FP: fluticasone propionate; ICS: inhaled corticosteroids; MOM: mometasone; pMDI: pressurised metered dose inhaler. </p> </div> </div> <div class="table" id="CD006924-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Children daily metred dose and delivery of beclomethasone, budesonide, fluticasone, or mometasone with formoterol</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on formoterol/ICS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on ICS alone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose (µg), (steroid)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose formoterol (µg)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Once daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Twice daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combined inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Separate inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DPI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>pMDI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (weeks)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0013" title="AstraZenecaSD‐039‐0682 . A 12‐week randomised, double‐blind, parallel‐group, multi‐centre phase‐III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1005 (first received 1 June 2002). MoriceAH , PetersonS , BeckmanO , KukovaZ . Efficacy and safety of a new pressurised metered‐dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics2008;21(1):152‐9. [1094‐5539: (Print)] ">Morice 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>415</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BEC)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0028" title="AstraZenecaSD‐039‐0688 . Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 µg, 2 inhalations b.i.d.) compared to Pulmicort® (budesonide 100 mcg, 2 inhalations b.i.d.) and Pulmicort (budesonide 100 µg, 2 inhalations b.i.d.) plus Oxis® (formoterol 4.5 µg, 2 inhalations b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children: a double‐blind, double‐dummy, randomised, parallel‐group, phase III, multicentre 12‐week study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1003 (first received 1 March 2002). PohunekP , KunaP , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal2004;24(Suppl 48):379s. PohunekP , KunaP , JorupC , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology2006; Vol. 17, issue 6:458‐65. PohunekP , MatulkaM , RybnicekO , KoprivaF , HonomichlovaH , SvobodovaT . Dose‐related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology2004;15(1):32‐9. ">Pohunek 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0031" title="AstraZenecaSD‐039‐0714 . Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid‐using asthmatic adolescent patients: a double‐blind, double dummy, randomised, parallel group, phase III, multi‐centre study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=999 (first received 14 November 2008). ">SD‐039‐0714</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 to 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0032" title="AstraZenecaSD‐039‐0718 . Symbicort in asthmatic children ‐ SEEDLING [A 12 week randomized, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (40/4.5 mcg) versus its mono‐products (budesonide and formoterol) in asthmatic children aged six to eleven years ‐ SEEDLING 40/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=968 (first received14 November 2008). PearlmanDS , MurphyKR , UryniakT , O'BrienCD , MezzanotteWS , DenverM . Safety of budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children with asthma previously treated with inhaled corticosteroids (ICSs) [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto#A710 (#K67). ">SD‐039‐0718</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0033" title="AstraZenecaSD‐039‐0719 . Long‐term safety of Symbicort in asthmatic children ‐ SAPLING [A six‐month, randomized, open‐label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=967 (first received 14 November 2008). BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. BergerWE , LefleinJG , GellerDE , ParasuramanB , MillerCJ , O'BrienCD , et al. The safety and clinical benefit of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings2010;31(1):26‐39. BergerWE , LefleinJG , UryniakT , O'BrienCD , O'DowdL . Long‐term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. LefleinJG , BergerWE , UryniakT , VervaetP , O'DowdL , O'BrienCD . Long‐term safety and systemic effects of budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S155. O'DowdL , BergerWE , LefleinJG , UryniakT , ParasuramanB , O'BrienCD . Health‐related quality of life (HRQL) and asthma control after long‐term treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152. ">SD‐039‐0719</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0034" title="AstraZenecaSD‐039‐0725 . Efficacy of Symbicort pMDI administered once daily in children and adolescents during 12 weeks ‐ SPROUT [A twelve‐week, randomized, double‐blind, double‐dummy, active‐controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma ‐ SPROUT]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=966 (first received 1 April 2003). EidNS , NoonanMJ , ChippsB , ParasuramanB , MillerCJ , O'BrienCD . Once‐ vs twice‐daily budesonide/formoterol in 6‐ to 15‐year‐old patients with stable asthma. Pediatrics2010;126(3):e565‐75. ">SD‐039‐0725</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0038" title="AstraZenecaSD‐039‐0353 . Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid‐using asthmatic children. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1019 (first received 1 November 1998). TalA , SimonG , VermeulenJH . Symbicort® budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology2002;34(5):342‐50. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. European Respiratory Journal2001;18(Suppl 33):494s. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; 2001 April 1‐4; Prague. 2001:84‐5. TalA , SimonG , VermeulenJH , VitP , CobosN , EverardML , et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal2000;16(Suppl 31):384s. VermeulenJH , SimonG , TalA . Symbicort® budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4‐17 years. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D29. ">Tal 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: BEC: beclomethasone; BUD: budesonide; DPI: dry powder inhaler; FP: fluticasone propionate; ICS: inhaled corticosteroids; MOM: mometasone; pMDI: pressurised metered dose inhaler. </p> </div> </div> <p><a href="#CD006924-tbl-0003">Table 1</a> and <a href="#CD006924-tbl-0004">Table 2</a> also indicate whether each study randomly assigned participants to once‐ or twice‐daily formoterol; used combined or separate inhalers; and delivered the medication using dry powder inhaler (DPI) or pressurised metred‐dose inhalers (pMDIs). Some trials had more than two arms and so featured more than one option in each of these cases. Because OPTIMA (<a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>), FACET (<a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>), and <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> randomly assigned participants to higher and lower doses of budesonide, each has been considered as two separate comparisons. </p> <p>All the trials on beclomethasone and formoterol were sponsored by Chiesi Farmaceutica (<a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a>; <a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a>; <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>); trials on budesonide and formoterol were sponsored or supported by AstraZeneca, Ache Laboratorios Farmaceuticos, the Japanese Society for the Promotion of Science, and Medical University of Lodz (<a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a>; <a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a>; <a href="./references#CD006924-bbs2-0003" title="ChuchalinA , StahlE , SvenssonK , OvcharenkoS , GoriachkinaL , SidorenkoI , et al. Formoterol (Oxis(r)) Turbuhaler(r) plus budesonide Turbuhaler(r) and budesonide alone improve health‐related quality of life vs non‐steroid therapy in mild to moderate asthma in Russia [Abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN . Formoterol Oxis® Turbuhaler® plus budesonide Turbuhaler® is more effective than current non‐steroid therapy and budesonide alone in mild to moderate asthma in Russia. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN , EPOCH Study Group. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non‐corticosteroid therapy in Russia. International Journal of Clinical Practice2002; Vol. 56, issue 1:15‐20. ChuchalinAG , SvenssonK , StahlE , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , et al. A health‐related quality‐of‐life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration2002;69(5):427‐33. ">Chuchalin 2002</a>; <a href="./references#CD006924-bbs2-0004" title="AstraZenecaSD‐039‐0716 . Efficacy of Symbicort versus its mono components ‐ SPRUCE 80/4.5 [A 12 week randomised, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (160/4.5mcg) versus its mono‐products (budesonide and formoterol) in children (at least 6 years of age) and adults with Asthma‐SPRUCE 80/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=970 (first received 1 August 2002). CorrenJ , KorenblatPE , MillerCJ , O'BrienCD , MezzanotteWS . Twelve‐week, randomised, placebo‐controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered‐dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics2007; Vol. 29, issue 5:823‐43. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in adults with mild to moderate persistent asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:928. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . The effect of budesonide and formoterol in one pressurized metered‐dose inhaler on patient‐reported outcomes in adults with mild‐to‐moderate persistent asthma. Current Medical Research and Opinion2008;24(3):879‐94. ">Corren 2007</a>; <a href="./references#CD006924-bbs2-0006" title="AstraZenecaD58960001 . Gemini Symbicort pMDI [A randomized, double‐blind, active‐controlled, parallel‐group, single dummy, multicenter, 12 week study to assess the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations once‐daily (qd) compared to SYMBICORT pMDI 80/4.5 μg × 2 actuations qd, SYMBICORT pMDI80/4.5 μg × 2 actuations twice‐daily (bid) and to budesonide pMDI 160 μg × 2 actuations qd in asthmatic subjects 12 years of age and older]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1581 (first received 20 October 2003). KerwinEM , OppenheimerJJ , LaForceC , MillerCJ , O'DowdL , GoldmanM . Effects on pulmonary function of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152‐3. LaForceC , KerwinEM , OppenheimerJJ , MillerCJ , VervaetP , O'DowdL , et al. Safety of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S153. OppenheimerJJ , KerwinEM , LaForceC , MillerCJ , O'DowdL , GoldmanM . Asthma control with once‐daily (qd) budesonide/formoterol pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. ">D5896C00001</a>; <a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a>; <a href="./references#CD006924-bbs2-0009" title="AstraZenecaSD‐039‐0665 . Symbicort low dose once daily in mild to moderate asthmatic patients. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1013 (first received 1 November 1999). KunaP , ChuchalinA , RingdalN , De laPadillaEA , BlackP , LindqvistA , et al. Low‐dose single‐inhaler budesonide/formoterol administered once daily is effective in mild‐persistent asthma. European Respiratory Journal2001;18(Suppl 33):158s. KunaP , CreemersJ , VondraV , BlackPN , LindqvistA , NihlenU , et al. Once‐daily dosing with budesonide/formoterol compared with twice‐daily budesonide/formoterol and once‐daily budesonide in adults with mild to moderate asthma. Respiratory Medicine2006; Vol. 100, issue 12:2151‐9. ">Kuna 2006</a>; <a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0012" title="AstraZeneca . A randomised, double‐blind, parallel‐group, multi centre phase‐III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 160/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 200 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 160/4.5 mcg 2 inhalations b.i.d., delivered dose) in adolescents and adults with asthma. www.astrazenecaclinicaltrials.com/search/?itemId=8574676 (first received 26 November 2008). MoriceAH , HochmuthL , PutermanA , ArthedenL , BeckmanO . Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy and Clinical Immunology2005; Vol. 115, issue 2 Suppl:S3. MoriceAH , PetersonS , BeckmanO , OsmanlievD . Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice2007;61(11):1874‐83. [1368‐5031: (Print)] ">Morice 2007</a>; <a href="./references#CD006924-bbs2-0013" title="AstraZenecaSD‐039‐0682 . A 12‐week randomised, double‐blind, parallel‐group, multi‐centre phase‐III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1005 (first received 1 June 2002). MoriceAH , PetersonS , BeckmanO , KukovaZ . Efficacy and safety of a new pressurised metered‐dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics2008;21(1):152‐9. [1094‐5539: (Print)] ">Morice 2008</a>; <a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a>; <a href="./references#CD006924-bbs2-0018" title="AstraZenecaSD‐039‐0717 . A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐controlled trial of SYMBICORT® (160/4.5 mcg) versus its mono‐products (budesonide and formoterol) in adolescents (&gt; 12 years of age) and adults with asthma, international. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=969 (first received 1 July 2002). BakerJ , MartinP , ParasuramanB . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in patients with asthma. Chest2007;132(4):509b. NoonanM , RosenwasserLJ , MartinP , O'BrienCD , O'DowdL . Efficacy and safety of budesonide and formoterol in one pressurised metered‐dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs2006;66(17):2235‐54. NoonanMJ , EidNS , UryniakT , O'BrienCD . Safety of once daily (qd) budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children and adolescents with asthma previously stable on twice daily (bid) BUD/FM pMDI [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:Abstract 711 [#K71]. RosenwasserLJ , NoonanMJ , MartinP , O'DowdL , O'BrienCD . Safety of budesonide and formoterol administered via one pressurized metered dose inhaler (budesonide/formoterol pMDI) in patients (&gt;12 years) with moderate to severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S5. Abstract 17. ">Noonan 2006</a>; <a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a>; <a href="./references#CD006924-bbs2-0025" title="AstraZenecaSD‐039‐0728 . Titratable dosing in moderate to severe asthmatics [A 52‐week, randomized, double‐blind, single‐dummy, parallel‐group, multicenter Phase III study comparing the long‐term safety of SYMBICORT® pMDI 160/4.5 mcg × 4 actuations twice daily to SYMBICORT® pMDI 160/4.5 mcg × 2 actuations twice daily and budesonide HFA pMDI 160 mcg × 4 actuations twice daily in adult and adolescent subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=964 (first received 1 August 2003). LawranceR , AmbroseH , GoldmanM . Effect of gly16arg beta2‐adrenergic receptor variation on the long‐term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered‐dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #420. O'BrienCD , PetersSP , PrennerBM , MartinP . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L57. O'BrienCD , PetersSP , PrennerBM , MartinP . Resource use with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L58. PetersSP , PrennerBM , MartinP , O'BrienCD . Long‐term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered‐dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #K5. PetersSP , PrennerBM , MezzanotteWS , MartinP , O'BrienCD . Long‐term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered‐dose inhaler in asthma. Allergy and Asthma Proceedings2008;29:1‐18. PrennerBM , PetersSP , MartinP , O'BrienCD . Long‐term control of asthma symptoms with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L67. PrennerBM , PetersSP , MartinP , O'BrienCD . Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/FM) pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:#L66. TashkinD , ChippsB , BrownR , UryniakT , TrudoF . Responder analysis evaluating the long‐term treatment of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in patients with moderate to severe asthma with versus without fixed airflow obstruction (FAO) [Abstract]. Chest2013;144:4. [DOI: 79A] ">Peters 2008</a>; <a href="./references#CD006924-bbs2-0028" title="AstraZenecaSD‐039‐0688 . Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 µg, 2 inhalations b.i.d.) compared to Pulmicort® (budesonide 100 mcg, 2 inhalations b.i.d.) and Pulmicort (budesonide 100 µg, 2 inhalations b.i.d.) plus Oxis® (formoterol 4.5 µg, 2 inhalations b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children: a double‐blind, double‐dummy, randomised, parallel‐group, phase III, multicentre 12‐week study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1003 (first received 1 March 2002). PohunekP , KunaP , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal2004;24(Suppl 48):379s. PohunekP , KunaP , JorupC , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology2006; Vol. 17, issue 6:458‐65. PohunekP , MatulkaM , RybnicekO , KoprivaF , HonomichlovaH , SvobodovaT . Dose‐related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology2004;15(1):32‐9. ">Pohunek 2006</a>; <a href="./references#CD006924-bbs2-0029" title="PriceD , DutchmanD , MawsonA , BodaliaB , DugganS , ToddP . Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax2002;57(9):791‐8. [0040‐6376: (Print)] PriceMJ , BriggsAH . Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics2002;20(3):183‐94. PriceMJ , SondhiS , YanS , NythA , HouseK . Salmeterol/fluticasone propionate combination inhaler is more cost effective than fluticasone propionate in patients with asthma. European Respiratory Society 9th Annual Congress; 1999 Oct 9‐13; Madrid. 1999:#2459. ">Price 2002</a>; <a href="./references#CD006924-bbs2-0031" title="AstraZenecaSD‐039‐0714 . Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid‐using asthmatic adolescent patients: a double‐blind, double dummy, randomised, parallel group, phase III, multi‐centre study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=999 (first received 14 November 2008). ">SD‐039‐0714</a>; <a href="./references#CD006924-bbs2-0032" title="AstraZenecaSD‐039‐0718 . Symbicort in asthmatic children ‐ SEEDLING [A 12 week randomized, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (40/4.5 mcg) versus its mono‐products (budesonide and formoterol) in asthmatic children aged six to eleven years ‐ SEEDLING 40/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=968 (first received14 November 2008). PearlmanDS , MurphyKR , UryniakT , O'BrienCD , MezzanotteWS , DenverM . Safety of budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children with asthma previously treated with inhaled corticosteroids (ICSs) [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto#A710 (#K67). ">SD‐039‐0718</a>; <a href="./references#CD006924-bbs2-0033" title="AstraZenecaSD‐039‐0719 . Long‐term safety of Symbicort in asthmatic children ‐ SAPLING [A six‐month, randomized, open‐label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=967 (first received 14 November 2008). BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. BergerWE , LefleinJG , GellerDE , ParasuramanB , MillerCJ , O'BrienCD , et al. The safety and clinical benefit of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings2010;31(1):26‐39. BergerWE , LefleinJG , UryniakT , O'BrienCD , O'DowdL . Long‐term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. LefleinJG , BergerWE , UryniakT , VervaetP , O'DowdL , O'BrienCD . Long‐term safety and systemic effects of budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S155. O'DowdL , BergerWE , LefleinJG , UryniakT , ParasuramanB , O'BrienCD . Health‐related quality of life (HRQL) and asthma control after long‐term treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152. ">SD‐039‐0719</a>; <a href="./references#CD006924-bbs2-0034" title="AstraZenecaSD‐039‐0725 . Efficacy of Symbicort pMDI administered once daily in children and adolescents during 12 weeks ‐ SPROUT [A twelve‐week, randomized, double‐blind, double‐dummy, active‐controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma ‐ SPROUT]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=966 (first received 1 April 2003). EidNS , NoonanMJ , ChippsB , ParasuramanB , MillerCJ , O'BrienCD . Once‐ vs twice‐daily budesonide/formoterol in 6‐ to 15‐year‐old patients with stable asthma. Pediatrics2010;126(3):e565‐75. ">SD‐039‐0725</a>; <a href="./references#CD006924-bbs2-0035" title="AstraZenecaSD‐039‐0726 . Efficacy of Symbicort pMDI administered once daily in adolescents and adults during 12 weeks ‐ STEM [A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma ‐ STEM]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=965 (first received 1 April 2003). ">SD‐039‐0726</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>; <a href="./references#CD006924-bbs2-0038" title="AstraZenecaSD‐039‐0353 . Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid‐using asthmatic children. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1019 (first received 1 November 1998). TalA , SimonG , VermeulenJH . Symbicort® budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology2002;34(5):342‐50. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. European Respiratory Journal2001;18(Suppl 33):494s. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; 2001 April 1‐4; Prague. 2001:84‐5. TalA , SimonG , VermeulenJH , VitP , CobosN , EverardML , et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal2000;16(Suppl 31):384s. VermeulenJH , SimonG , TalA . Symbicort® budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4‐17 years. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D29. ">Tal 2002</a>; <a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a>); and all the trials on mometasone and formoterol were sponsored by Merck or Schering‐Plough (<a href="./references#CD006924-bbs2-0011" title="MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10µg twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids. World Allergy Organization Journal2012;5 (Suppl 2):S80‐1. MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:1203. MeltzerE , NolteH , LaforceC . Low‐dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology2009;A66:P92. MeltzerEO , KunaP , NolteH , NayakAS , LaforceC . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal2012;39(2):279‐89. [1399‐3003: (Electronic)] MeltzerEO , NolteH , LaForceC . Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice‐daily administered via a pressurized metered‐dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A5661. ">Meltzer 2012</a>; <a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a>; <a href="./references#CD006924-bbs2-0039" title="NCT00381485 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED) [A 12‐week efficacy and safety study of two doses of mometasone furoate/formoterol combination formulation compared with mometasone furoate monotherapy, in persistent asthmatics previously treated with high‐dose inhaled glucocorticosteroids]. clinicaltrials.gov/ct2/show/NCT00381485 (first received 27 September 2006). [NCT00381485] NolteH , WhiteM , WeinsteinSF , NathanRA , GatesD , MeltzerEO . Evaluation of diary data on asthma control factors managed with combined mometasone furoate and formoterol fumarate in patients with severe asthma. Respirology2012;17 (Suppl 2):1‐16. WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB196. [0091‐6749] WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. European Respiratory Society https://www.ers‐education.org/home/browse‐all‐content.aspx?idParent=861112010;36(Suppl 54):5482. WeinsteinS , MurphyK , NolteH . Efficacy and safety of two doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. World Allergy Organization. 2012:S79‐80. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered‐dose inhaler device. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5411. WeinsteinS , WhiteM , CorrenJ , NolteH . Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna. 2009:E280. WeinsteinSF , CorrenJ , MurphyK , NolteH , WhiteM . Twelve‐week efficacy and safety study of mometasone furoate/formoterol 200/10 [micro]g and 400/10 [micro]g combination treatments in patients with persistent asthma previously receiving high‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):280‐9. WeinsteinSF , WhiteM , CorrenJ , NolteH . Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered‐dose inhaler (MDI), in severe asthma patients previously treated with high‐dose inhaled corticosteroids (ICS). American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:J53. ">Weinstein 2010</a>; <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>). Trials on fluticasone and formoterol were sponsored by Mundipharma Research Ltd, Skyepharma, and Skyepharma/Abbott Respiratory LLC (<a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a>; <a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a>; <a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a>; <a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a>; <a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a>). </p> <section id="CD006924-sec-0064"> <h5 class="title">Adults</h5> <p>We included 29 trials with a total of 37,984 adults (aged 12 years and over) (<a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a>; <a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a>; <a href="./references#CD006924-bbs2-0003" title="ChuchalinA , StahlE , SvenssonK , OvcharenkoS , GoriachkinaL , SidorenkoI , et al. Formoterol (Oxis(r)) Turbuhaler(r) plus budesonide Turbuhaler(r) and budesonide alone improve health‐related quality of life vs non‐steroid therapy in mild to moderate asthma in Russia [Abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN . Formoterol Oxis® Turbuhaler® plus budesonide Turbuhaler® is more effective than current non‐steroid therapy and budesonide alone in mild to moderate asthma in Russia. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN , EPOCH Study Group. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non‐corticosteroid therapy in Russia. International Journal of Clinical Practice2002; Vol. 56, issue 1:15‐20. ChuchalinAG , SvenssonK , StahlE , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , et al. A health‐related quality‐of‐life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration2002;69(5):427‐33. ">Chuchalin 2002</a>; <a href="./references#CD006924-bbs2-0004" title="AstraZenecaSD‐039‐0716 . Efficacy of Symbicort versus its mono components ‐ SPRUCE 80/4.5 [A 12 week randomised, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (160/4.5mcg) versus its mono‐products (budesonide and formoterol) in children (at least 6 years of age) and adults with Asthma‐SPRUCE 80/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=970 (first received 1 August 2002). CorrenJ , KorenblatPE , MillerCJ , O'BrienCD , MezzanotteWS . Twelve‐week, randomised, placebo‐controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered‐dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics2007; Vol. 29, issue 5:823‐43. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in adults with mild to moderate persistent asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:928. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . The effect of budesonide and formoterol in one pressurized metered‐dose inhaler on patient‐reported outcomes in adults with mild‐to‐moderate persistent asthma. Current Medical Research and Opinion2008;24(3):879‐94. ">Corren 2007</a>; <a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a>; <a href="./references#CD006924-bbs2-0006" title="AstraZenecaD58960001 . Gemini Symbicort pMDI [A randomized, double‐blind, active‐controlled, parallel‐group, single dummy, multicenter, 12 week study to assess the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations once‐daily (qd) compared to SYMBICORT pMDI 80/4.5 μg × 2 actuations qd, SYMBICORT pMDI80/4.5 μg × 2 actuations twice‐daily (bid) and to budesonide pMDI 160 μg × 2 actuations qd in asthmatic subjects 12 years of age and older]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1581 (first received 20 October 2003). KerwinEM , OppenheimerJJ , LaForceC , MillerCJ , O'DowdL , GoldmanM . Effects on pulmonary function of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152‐3. LaForceC , KerwinEM , OppenheimerJJ , MillerCJ , VervaetP , O'DowdL , et al. Safety of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S153. OppenheimerJJ , KerwinEM , LaForceC , MillerCJ , O'DowdL , GoldmanM . Asthma control with once‐daily (qd) budesonide/formoterol pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. ">D5896C00001</a>; <a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a>; <a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a>; <a href="./references#CD006924-bbs2-0009" title="AstraZenecaSD‐039‐0665 . Symbicort low dose once daily in mild to moderate asthmatic patients. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1013 (first received 1 November 1999). KunaP , ChuchalinA , RingdalN , De laPadillaEA , BlackP , LindqvistA , et al. Low‐dose single‐inhaler budesonide/formoterol administered once daily is effective in mild‐persistent asthma. European Respiratory Journal2001;18(Suppl 33):158s. KunaP , CreemersJ , VondraV , BlackPN , LindqvistA , NihlenU , et al. Once‐daily dosing with budesonide/formoterol compared with twice‐daily budesonide/formoterol and once‐daily budesonide in adults with mild to moderate asthma. Respiratory Medicine2006; Vol. 100, issue 12:2151‐9. ">Kuna 2006</a>; <a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0011" title="MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10µg twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids. World Allergy Organization Journal2012;5 (Suppl 2):S80‐1. MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:1203. MeltzerE , NolteH , LaforceC . Low‐dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology2009;A66:P92. MeltzerEO , KunaP , NolteH , NayakAS , LaforceC . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal2012;39(2):279‐89. [1399‐3003: (Electronic)] MeltzerEO , NolteH , LaForceC . Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice‐daily administered via a pressurized metered‐dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A5661. ">Meltzer 2012</a>; <a href="./references#CD006924-bbs2-0012" title="AstraZeneca . A randomised, double‐blind, parallel‐group, multi centre phase‐III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 160/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 200 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 160/4.5 mcg 2 inhalations b.i.d., delivered dose) in adolescents and adults with asthma. www.astrazenecaclinicaltrials.com/search/?itemId=8574676 (first received 26 November 2008). MoriceAH , HochmuthL , PutermanA , ArthedenL , BeckmanO . Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy and Clinical Immunology2005; Vol. 115, issue 2 Suppl:S3. MoriceAH , PetersonS , BeckmanO , OsmanlievD . Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice2007;61(11):1874‐83. [1368‐5031: (Print)] ">Morice 2007</a>; <a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a>; <a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a>; <a href="./references#CD006924-bbs2-0016" title="NathanRA , D'UrzoA , BlazhkoV , KaiserK . Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine2012;12:67. [NCT00393991] ">Nathan 2012</a>; <a href="./references#CD006924-bbs2-0018" title="AstraZenecaSD‐039‐0717 . A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐controlled trial of SYMBICORT® (160/4.5 mcg) versus its mono‐products (budesonide and formoterol) in adolescents (&gt; 12 years of age) and adults with asthma, international. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=969 (first received 1 July 2002). BakerJ , MartinP , ParasuramanB . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in patients with asthma. Chest2007;132(4):509b. NoonanM , RosenwasserLJ , MartinP , O'BrienCD , O'DowdL . Efficacy and safety of budesonide and formoterol in one pressurised metered‐dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs2006;66(17):2235‐54. NoonanMJ , EidNS , UryniakT , O'BrienCD . Safety of once daily (qd) budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children and adolescents with asthma previously stable on twice daily (bid) BUD/FM pMDI [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:Abstract 711 [#K71]. RosenwasserLJ , NoonanMJ , MartinP , O'DowdL , O'BrienCD . Safety of budesonide and formoterol administered via one pressurized metered dose inhaler (budesonide/formoterol pMDI) in patients (&gt;12 years) with moderate to severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S5. Abstract 17. ">Noonan 2006</a>; <a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a>; <a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a>; <a href="./references#CD006924-bbs2-0025" title="AstraZenecaSD‐039‐0728 . Titratable dosing in moderate to severe asthmatics [A 52‐week, randomized, double‐blind, single‐dummy, parallel‐group, multicenter Phase III study comparing the long‐term safety of SYMBICORT® pMDI 160/4.5 mcg × 4 actuations twice daily to SYMBICORT® pMDI 160/4.5 mcg × 2 actuations twice daily and budesonide HFA pMDI 160 mcg × 4 actuations twice daily in adult and adolescent subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=964 (first received 1 August 2003). LawranceR , AmbroseH , GoldmanM . Effect of gly16arg beta2‐adrenergic receptor variation on the long‐term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered‐dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #420. O'BrienCD , PetersSP , PrennerBM , MartinP . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L57. O'BrienCD , PetersSP , PrennerBM , MartinP . Resource use with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L58. PetersSP , PrennerBM , MartinP , O'BrienCD . Long‐term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered‐dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #K5. PetersSP , PrennerBM , MezzanotteWS , MartinP , O'BrienCD . Long‐term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered‐dose inhaler in asthma. Allergy and Asthma Proceedings2008;29:1‐18. PrennerBM , PetersSP , MartinP , O'BrienCD . Long‐term control of asthma symptoms with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L67. PrennerBM , PetersSP , MartinP , O'BrienCD . Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/FM) pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:#L66. TashkinD , ChippsB , BrownR , UryniakT , TrudoF . Responder analysis evaluating the long‐term treatment of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in patients with moderate to severe asthma with versus without fixed airflow obstruction (FAO) [Abstract]. Chest2013;144:4. [DOI: 79A] ">Peters 2008</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>; <a href="./references#CD006924-bbs2-0029" title="PriceD , DutchmanD , MawsonA , BodaliaB , DugganS , ToddP . Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax2002;57(9):791‐8. [0040‐6376: (Print)] PriceMJ , BriggsAH . Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics2002;20(3):183‐94. PriceMJ , SondhiS , YanS , NythA , HouseK . Salmeterol/fluticasone propionate combination inhaler is more cost effective than fluticasone propionate in patients with asthma. European Respiratory Society 9th Annual Congress; 1999 Oct 9‐13; Madrid. 1999:#2459. ">Price 2002</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0031" title="AstraZenecaSD‐039‐0714 . Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid‐using asthmatic adolescent patients: a double‐blind, double dummy, randomised, parallel group, phase III, multi‐centre study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=999 (first received 14 November 2008). ">SD‐039‐0714</a>; <a href="./references#CD006924-bbs2-0035" title="AstraZenecaSD‐039‐0726 . Efficacy of Symbicort pMDI administered once daily in adolescents and adults during 12 weeks ‐ STEM [A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma ‐ STEM]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=965 (first received 1 April 2003). ">SD‐039‐0726</a>; <a href="./references#CD006924-bbs2-0036" title="AstraZenecaD589BL00003 . Phase4/Symbicort® versus Pulmicort Flexhaler® in African Americans (Titan) [A 12‐week, randomized, double‐blind, double‐dummy, multi‐center, phase IV study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations twice daily versus budesonide inhalation powder DPI 180 μg × 2 inhalations twice daily, in adult and adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1614 (first received 1 June 2008). [D589BL00003] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Budesonide/formoterol pressurized metered‐dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. Journal of Asthma2012;49(1):70‐7. [1532‐4303: (Electronic)] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Effect of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(Suppl):5. SpectorSL , O'BrienCD , UryniakT , MartinUJ . Safety and tolerability of a budesonide/formoterol (BUD/FM) pressurized metered‐dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Chest2010;138(4):705A. ">Spector 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>; <a href="./references#CD006924-bbs2-0039" title="NCT00381485 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED) [A 12‐week efficacy and safety study of two doses of mometasone furoate/formoterol combination formulation compared with mometasone furoate monotherapy, in persistent asthmatics previously treated with high‐dose inhaled glucocorticosteroids]. clinicaltrials.gov/ct2/show/NCT00381485 (first received 27 September 2006). [NCT00381485] NolteH , WhiteM , WeinsteinSF , NathanRA , GatesD , MeltzerEO . Evaluation of diary data on asthma control factors managed with combined mometasone furoate and formoterol fumarate in patients with severe asthma. Respirology2012;17 (Suppl 2):1‐16. WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB196. [0091‐6749] WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. European Respiratory Society https://www.ers‐education.org/home/browse‐all‐content.aspx?idParent=861112010;36(Suppl 54):5482. WeinsteinS , MurphyK , NolteH . Efficacy and safety of two doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. World Allergy Organization. 2012:S79‐80. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered‐dose inhaler device. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5411. WeinsteinS , WhiteM , CorrenJ , NolteH . Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna. 2009:E280. WeinsteinSF , CorrenJ , MurphyK , NolteH , WhiteM . Twelve‐week efficacy and safety study of mometasone furoate/formoterol 200/10 [micro]g and 400/10 [micro]g combination treatments in patients with persistent asthma previously receiving high‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):280‐9. WeinsteinSF , WhiteM , CorrenJ , NolteH . Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered‐dose inhaler (MDI), in severe asthma patients previously treated with high‐dose inhaled corticosteroids (ICS). American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:J53. ">Weinstein 2010</a>; <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>; <a href="./references#CD006924-bbs2-0041" title="NCT00419757 . An efficacy study comparing SYMBICORT® pressurised metered dose Iinhaler (pMDI) with budesonide hydrofluoroalkanes (HFA) pMDI, in hispanic subjects with ICS dependent asthma [A 12‐week, randomised, double blind, active‐controlled, multi‐centre, phase IIIB study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily versus budesonide HFA pMDI 160 mg x 2 actuations twice daily, in adult/adolescent (&gt; 12 Yrs) Hispanic subjects with asthma]. clinicaltrials.gov/ct2/show/NCT00419757 (first received 9 January 2007). [NCT00419757] ZangrilliJ , MansfieldLE , UryniakT , O'BrienCD . Efficacy of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide pressurized metered‐dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Annals of Allergy, Asthma and Immunology2011;107:258‐65. ">Zangrilli 2011</a>; <a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a>). Eleven of these trials enrolled adults aged 18 years and over (<a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a>; <a href="./references#CD006924-bbs2-0003" title="ChuchalinA , StahlE , SvenssonK , OvcharenkoS , GoriachkinaL , SidorenkoI , et al. Formoterol (Oxis(r)) Turbuhaler(r) plus budesonide Turbuhaler(r) and budesonide alone improve health‐related quality of life vs non‐steroid therapy in mild to moderate asthma in Russia [Abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN . Formoterol Oxis® Turbuhaler® plus budesonide Turbuhaler® is more effective than current non‐steroid therapy and budesonide alone in mild to moderate asthma in Russia. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN , EPOCH Study Group. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non‐corticosteroid therapy in Russia. International Journal of Clinical Practice2002; Vol. 56, issue 1:15‐20. ChuchalinAG , SvenssonK , StahlE , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , et al. A health‐related quality‐of‐life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration2002;69(5):427‐33. ">Chuchalin 2002</a>; <a href="./references#CD006924-bbs2-0009" title="AstraZenecaSD‐039‐0665 . Symbicort low dose once daily in mild to moderate asthmatic patients. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1013 (first received 1 November 1999). KunaP , ChuchalinA , RingdalN , De laPadillaEA , BlackP , LindqvistA , et al. Low‐dose single‐inhaler budesonide/formoterol administered once daily is effective in mild‐persistent asthma. European Respiratory Journal2001;18(Suppl 33):158s. KunaP , CreemersJ , VondraV , BlackPN , LindqvistA , NihlenU , et al. Once‐daily dosing with budesonide/formoterol compared with twice‐daily budesonide/formoterol and once‐daily budesonide in adults with mild to moderate asthma. Respiratory Medicine2006; Vol. 100, issue 12:2151‐9. ">Kuna 2006</a>; <a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>; <a href="./references#CD006924-bbs2-0039" title="NCT00381485 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED) [A 12‐week efficacy and safety study of two doses of mometasone furoate/formoterol combination formulation compared with mometasone furoate monotherapy, in persistent asthmatics previously treated with high‐dose inhaled glucocorticosteroids]. clinicaltrials.gov/ct2/show/NCT00381485 (first received 27 September 2006). [NCT00381485] NolteH , WhiteM , WeinsteinSF , NathanRA , GatesD , MeltzerEO . Evaluation of diary data on asthma control factors managed with combined mometasone furoate and formoterol fumarate in patients with severe asthma. Respirology2012;17 (Suppl 2):1‐16. WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB196. [0091‐6749] WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. European Respiratory Society https://www.ers‐education.org/home/browse‐all‐content.aspx?idParent=861112010;36(Suppl 54):5482. WeinsteinS , MurphyK , NolteH . Efficacy and safety of two doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. World Allergy Organization. 2012:S79‐80. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered‐dose inhaler device. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5411. WeinsteinS , WhiteM , CorrenJ , NolteH . Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna. 2009:E280. WeinsteinSF , CorrenJ , MurphyK , NolteH , WhiteM . Twelve‐week efficacy and safety study of mometasone furoate/formoterol 200/10 [micro]g and 400/10 [micro]g combination treatments in patients with persistent asthma previously receiving high‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):280‐9. WeinsteinSF , WhiteM , CorrenJ , NolteH . Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered‐dose inhaler (MDI), in severe asthma patients previously treated with high‐dose inhaled corticosteroids (ICS). American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:J53. ">Weinstein 2010</a>; <a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a>). </p> <p>Participants mostly had forced expiratory volume in 1 second (FEV<sub>1</sub>) &lt; 80% predicted. The mean age of participants was 34 years (so although small numbers of adolescents may have been included, we have reported these as adult studies). None of these studies reported separate results for adolescents, so all participants in these studies have been analysed as adults. </p> <p>The weighted mean duration of the adult trials was 26 weeks. The daily metered dose of formoterol used ranged from 12 to 24 µg, with the exception of <a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a> and <a href="./references#CD006924-bbs2-0025" title="AstraZenecaSD‐039‐0728 . Titratable dosing in moderate to severe asthmatics [A 52‐week, randomized, double‐blind, single‐dummy, parallel‐group, multicenter Phase III study comparing the long‐term safety of SYMBICORT® pMDI 160/4.5 mcg × 4 actuations twice daily to SYMBICORT® pMDI 160/4.5 mcg × 2 actuations twice daily and budesonide HFA pMDI 160 mcg × 4 actuations twice daily in adult and adolescent subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=964 (first received 1 August 2003). LawranceR , AmbroseH , GoldmanM . Effect of gly16arg beta2‐adrenergic receptor variation on the long‐term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered‐dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #420. O'BrienCD , PetersSP , PrennerBM , MartinP . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L57. O'BrienCD , PetersSP , PrennerBM , MartinP . Resource use with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L58. PetersSP , PrennerBM , MartinP , O'BrienCD . Long‐term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered‐dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #K5. PetersSP , PrennerBM , MezzanotteWS , MartinP , O'BrienCD . Long‐term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered‐dose inhaler in asthma. Allergy and Asthma Proceedings2008;29:1‐18. PrennerBM , PetersSP , MartinP , O'BrienCD . Long‐term control of asthma symptoms with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L67. PrennerBM , PetersSP , MartinP , O'BrienCD . Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/FM) pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:#L66. TashkinD , ChippsB , BrownR , UryniakT , TrudoF . Responder analysis evaluating the long‐term treatment of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in patients with moderate to severe asthma with versus without fixed airflow obstruction (FAO) [Abstract]. Chest2013;144:4. [DOI: 79A] ">Peters 2008</a>, who used 48 µg daily (which remains within the licensed daily dosage range). The daily metered doses of beclomethasone were 800 µg; budesonide ranged from 200 to 1600 µg; fluticasone ranged from 200 to 500 µg; and mometasone from 200 to 800 µg (see <a href="#CD006924-tbl-0003">Table 1</a>). </p> </section> <section id="CD006924-sec-0065"> <h5 class="title">Children and adolescents</h5> <p>We included 10 trials in children and adolescents, which involved 4035 participants in the following age ranges: <a href="./references#CD006924-bbs2-0013" title="AstraZenecaSD‐039‐0682 . A 12‐week randomised, double‐blind, parallel‐group, multi‐centre phase‐III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1005 (first received 1 June 2002). MoriceAH , PetersonS , BeckmanO , KukovaZ . Efficacy and safety of a new pressurised metered‐dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics2008;21(1):152‐9. [1094‐5539: (Print)] ">Morice 2008</a>, 6 to 11 years old; <a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a>, 2 to 11; <a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a>, 6 to 12; <a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a>, 5 to 12; <a href="./references#CD006924-bbs2-0028" title="AstraZenecaSD‐039‐0688 . Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 µg, 2 inhalations b.i.d.) compared to Pulmicort® (budesonide 100 mcg, 2 inhalations b.i.d.) and Pulmicort (budesonide 100 µg, 2 inhalations b.i.d.) plus Oxis® (formoterol 4.5 µg, 2 inhalations b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children: a double‐blind, double‐dummy, randomised, parallel‐group, phase III, multicentre 12‐week study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1003 (first received 1 March 2002). PohunekP , KunaP , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal2004;24(Suppl 48):379s. PohunekP , KunaP , JorupC , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology2006; Vol. 17, issue 6:458‐65. PohunekP , MatulkaM , RybnicekO , KoprivaF , HonomichlovaH , SvobodovaT . Dose‐related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology2004;15(1):32‐9. ">Pohunek 2006</a>, 4 to 11; <a href="./references#CD006924-bbs2-0031" title="AstraZenecaSD‐039‐0714 . Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid‐using asthmatic adolescent patients: a double‐blind, double dummy, randomised, parallel group, phase III, multi‐centre study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=999 (first received 14 November 2008). ">SD‐039‐0714</a>, 11 to 17; <a href="./references#CD006924-bbs2-0032" title="AstraZenecaSD‐039‐0718 . Symbicort in asthmatic children ‐ SEEDLING [A 12 week randomized, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (40/4.5 mcg) versus its mono‐products (budesonide and formoterol) in asthmatic children aged six to eleven years ‐ SEEDLING 40/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=968 (first received14 November 2008). PearlmanDS , MurphyKR , UryniakT , O'BrienCD , MezzanotteWS , DenverM . Safety of budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children with asthma previously treated with inhaled corticosteroids (ICSs) [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto#A710 (#K67). ">SD‐039‐0718</a>, 6 to 15; <a href="./references#CD006924-bbs2-0033" title="AstraZenecaSD‐039‐0719 . Long‐term safety of Symbicort in asthmatic children ‐ SAPLING [A six‐month, randomized, open‐label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=967 (first received 14 November 2008). BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. BergerWE , LefleinJG , GellerDE , ParasuramanB , MillerCJ , O'BrienCD , et al. The safety and clinical benefit of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings2010;31(1):26‐39. BergerWE , LefleinJG , UryniakT , O'BrienCD , O'DowdL . Long‐term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. LefleinJG , BergerWE , UryniakT , VervaetP , O'DowdL , O'BrienCD . Long‐term safety and systemic effects of budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S155. O'DowdL , BergerWE , LefleinJG , UryniakT , ParasuramanB , O'BrienCD . Health‐related quality of life (HRQL) and asthma control after long‐term treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152. ">SD‐039‐0719</a>, 6 to 11; <a href="./references#CD006924-bbs2-0034" title="AstraZenecaSD‐039‐0725 . Efficacy of Symbicort pMDI administered once daily in children and adolescents during 12 weeks ‐ SPROUT [A twelve‐week, randomized, double‐blind, double‐dummy, active‐controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma ‐ SPROUT]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=966 (first received 1 April 2003). EidNS , NoonanMJ , ChippsB , ParasuramanB , MillerCJ , O'BrienCD . Once‐ vs twice‐daily budesonide/formoterol in 6‐ to 15‐year‐old patients with stable asthma. Pediatrics2010;126(3):e565‐75. ">SD‐039‐0725</a>, 6 to 15; and <a href="./references#CD006924-bbs2-0038" title="AstraZenecaSD‐039‐0353 . Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid‐using asthmatic children. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1019 (first received 1 November 1998). TalA , SimonG , VermeulenJH . Symbicort® budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology2002;34(5):342‐50. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. European Respiratory Journal2001;18(Suppl 33):494s. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; 2001 April 1‐4; Prague. 2001:84‐5. TalA , SimonG , VermeulenJH , VitP , CobosN , EverardML , et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal2000;16(Suppl 31):384s. VermeulenJH , SimonG , TalA . Symbicort® budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4‐17 years. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D29. ">Tal 2002</a>, 4 to 17. In all studies, the mean age of participants was younger than 18 years and mostly had FEV<sub>1</sub> &lt; 80% predicted. </p> <p>The weighted mean duration of studies of children and adolescents was 12.5 weeks. The daily metered dose of formoterol was 12 to 24 µg. The daily metered dose of budesonide was 200 to 400 µg, and fluticasone daily dose was 200 µg (see <a href="#CD006924-tbl-0004">Table 2</a>). </p> </section> </section> <section id="CD006924-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 74 studies with reasons described in <a href="./references#CD006924-sec-0139" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD006924-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>An overview of the risk of bias in individual studies is provided in <a href="#CD006924-fig-0002">Figure 2</a>; support for judgements in individual studies are shown in <a href="./references#CD006924-sec-0138" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD006924-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006924-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD006924-sec-0068"> <h4 class="title">Allocation</h4> <p>We assessed 23 studies as at low risk of bias for random sequence generation and 15 studies as at low risk of bias for allocation concealment. We found limited information available from paper publications or web reports on sequence generation or allocation concealment, but have considered that this is unlikely to be a source of bias because the studies were sponsored, and standard methodology would have been used to minimise the risk of selection bias. We therefore judged the risk of selection bias as low, although sequence generation and allocation concealment are marked as unclear in many of the studies in <a href="#CD006924-fig-0002">Figure 2</a>. </p> </section> <section id="CD006924-sec-0069"> <h4 class="title">Blinding</h4> <p>All of the studies were double‐blind with the exception of <a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a> and <a href="./references#CD006924-bbs2-0033" title="AstraZenecaSD‐039‐0719 . Long‐term safety of Symbicort in asthmatic children ‐ SAPLING [A six‐month, randomized, open‐label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=967 (first received 14 November 2008). BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. BergerWE , LefleinJG , GellerDE , ParasuramanB , MillerCJ , O'BrienCD , et al. The safety and clinical benefit of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings2010;31(1):26‐39. BergerWE , LefleinJG , UryniakT , O'BrienCD , O'DowdL . Long‐term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. LefleinJG , BergerWE , UryniakT , VervaetP , O'DowdL , O'BrienCD . Long‐term safety and systemic effects of budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S155. O'DowdL , BergerWE , LefleinJG , UryniakT , ParasuramanB , O'BrienCD . Health‐related quality of life (HRQL) and asthma control after long‐term treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152. ">SD‐039‐0719</a>, both of which were open‐label studies. We regarded the overall risk of performance and detection bias as low for the all‐cause events. </p> <section id="CD006924-sec-0070"> <h5 class="title">Independent outcome assessment (detection bias)</h5> <p>We were concerned that bias might have been introduced in the attribution of asthma as the cause of serious events, as this was not independently assessed in some of the included studies. Although the trials were double‐blind, formoterol can have a big impact on asthma symptoms, and those who decided on the cause of the events may have guessed which treatment was being given. </p> </section> </section> <section id="CD006924-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>The rate of withdrawals and dropouts was clearly reported and was generally less than 20% for randomly assigned participants; these rates were similar in the arms of each study. However, <a href="./references#CD006924-bbs2-0036" title="AstraZenecaD589BL00003 . Phase4/Symbicort® versus Pulmicort Flexhaler® in African Americans (Titan) [A 12‐week, randomized, double‐blind, double‐dummy, multi‐center, phase IV study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations twice daily versus budesonide inhalation powder DPI 180 μg × 2 inhalations twice daily, in adult and adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1614 (first received 1 June 2008). [D589BL00003] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Budesonide/formoterol pressurized metered‐dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. Journal of Asthma2012;49(1):70‐7. [1532‐4303: (Electronic)] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Effect of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(Suppl):5. SpectorSL , O'BrienCD , UryniakT , MartinUJ . Safety and tolerability of a budesonide/formoterol (BUD/FM) pressurized metered‐dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Chest2010;138(4):705A. ">Spector 2012</a> reported more withdrawals on budesonide alone (34% compared with 24% on combination treatment), so we judged this study to be at high risk of attrition bias. </p> </section> <section id="CD006924-sec-0072"> <h4 class="title">Selective reporting</h4> <p>Data were obtained from or provided by the sponsor for fatal and non‐fatal SAEs by treatment group and causation for all studies, except for <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>, which did not include details of either all‐cause or asthma‐related SAEs. </p> </section> <section id="CD006924-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>The majority of included studies were sponsored by manufacturers of combination products, but we did not regard sponsorship as necessarily increasing the risk of bias when studies were well designed. </p> </section> </section> <section id="CD006924-sec-0074"> <h3 class="title" id="CD006924-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD006924-tbl-0001"><b>Summary of findings for the main comparison</b> Regular formoterol and ICS compared to same‐dose ICS in adults with asthma</a>; <a href="./full#CD006924-tbl-0002"><b>Summary of findings 2</b> Regular formoterol and ICS compared to same‐dose ICS in children and adolescents with asthma</a> </p> <section id="CD006924-sec-0075"> <h4 class="title">Primary outcomes</h4> <section id="CD006924-sec-0076"> <h5 class="title">All‐cause mortality</h5> <section id="CD006924-sec-0077"> <h6 class="title">Adults</h6> <p>We included 29 studies in the analysis (participants = 35,751). Three studies compared low‐ and high‐dose formoterol plus ICS with ICS alone (<a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>). In the analysis, each treatment dose from the three studies was reported separately (resulting in 32 estimates of treatment effect), and the number of participants in the ICS only treatment group was halved (when necessary) to avoid double‐counting. </p> <p>Seventeen deaths were reported in 18,645 participants taking formoterol with ICS, and 13 deaths occurred out of 17,106 participants taking ICS alone. These trials were combined with the use of the Peto odds ratio (as no continuity correction for zero cells is required). The Peto OR of all‐cause mortality with formoterol was 1.25 (95% confidence interval (CI) 0.61 to 2.56; 29 studies; 35, 751 participants ; I<sup>2</sup> = 0%; <a href="#CD006924-fig-0003">Figure 3</a>; <a href="./references#CD006924-fig-0008" title="">Analysis 1.1</a>; <a href="#CD006924-tbl-0005">Table 3</a>). This means that for every 1000 adults treated for 26 weeks, one death occurred on ICS alone, and the corresponding risk for formoterol and ICS was also one death (95% CI 0 to 2). We assessed this evidence as of moderate certainty because only 30 deaths occurred in total across all of the trials (<a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>). We were, therefore, unable to conclude with high certainty that regular formoterol with ICS is as safe as regular ICS alone. </p> <div class="figure" id="CD006924-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.1 All‐cause mortality." data-id="CD006924-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.1 All‐cause mortality. </p> </div> </div> </div> <div class="table" id="CD006924-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of pooled odds ratios</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Peto OR meta‐analysis: regular formoterol in addition to regular ICS versus ICS alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events F/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N F/ICS </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peto OR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI start</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI end</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause non‐fatal serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.51</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; ICS: inhaled corticosteroids; F: formoterol; N: number of participants; OR: odds ratio. </p> </div> </div> <p>Reports on the cause of each death are documented in <a href="#CD006924-tbl-0006">Table 4</a>. </p> <div class="table" id="CD006924-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mortality by cause of death</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment given</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cause of death (N)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac arrest (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (separate inhalers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Status asthmaticus, followed by septic shock (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (separate inhalers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular accident (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Homicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and mometasone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uterine leiomyosarcoma (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary embolus (but the death occurred after the control budesonide arm was discontinued so was not included in the meta‐analysis) (1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (low dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Road traffic accident (1), suicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (high dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute myocardial infarction (1), electric shock (1), asthma‐related death (2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide (low dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pancytopenia (1), cerebrovascular event (1), pneumonitis (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide (high dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary artery insufficiency (1), myocardial ischaemia (1), death of unknown cause* (1), road traffic accident (1), cerebrovascular event (1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone and formoterol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1), cardiomyopathy (1), coronary artery thrombosis (1), chronic obstructive pulmonary disease (1), ischaemic stroke (1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1), pulmonary embolism (1), gastrointestinal necrosis (1), pneumonia (1)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*The participant died at home suddenly, with no history of exacerbation or other adverse or serious adverse event, and without consulting a health practitioner. </p> <p>Abbreviations: N: number of participants.</p> </div> </div> </section> <section id="CD006924-sec-0078"> <h6 class="title">Children and adolescents</h6> <p>No deaths were reported in trials on children and adolescents treated with formoterol and ICS or ICS alone (<a href="#CD006924-fig-0003">Figure 3</a>; <a href="./references#CD006924-fig-0008" title="">Analysis 1.1</a>). As it was not possible to calculate the OR from the data, we used the pooled risk difference (RD) to assess the data (RD 0.0000, 95% CI −0.0034 to 0.0034; 10 studies; 4035 participants ) (<a href="#CD006924-tbl-0007">Table 5</a>). This means that for every 1000 children treated with formoterol and ICS for 12.5 weeks, the 95% CI was compatible with a possible increase or decrease of three deaths. We assessed this evidence as of low certainty because no deaths were reported across the trials (<a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>; <a href="#CD006924-fig-0003">Figure 3</a>). We were unable to conclude that regular formoterol with ICS is as safe as regular ICS alone in terms of mortality, but the fact that there were no deaths is reassuring in terms of low mortality risks in trials on children in both groups. </p> <div class="table" id="CD006924-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of pooled risk differences</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Risk difference meta‐analysis: regular formoterol in addition to regular ICS versus ICS alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events F/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N F/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events ICS </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI start</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI end</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0034</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause non‐fatal serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0031</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0034</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0057</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; F: formoterol; ICS: inhaled corticosteroid; N: number of participants. </p> </div> </div> <p>The test for subgroup interaction between adults and children was not possible as there were no deaths in children. </p> </section> </section> <section id="CD006924-sec-0079"> <h5 class="title">All‐cause non‐fatal serious adverse events</h5> <p>A non‐fatal SAE is generally defined as an event that falls into any of the following categories. </p> <p> <ul id="CD006924-list-0008"> <li> <p>Is life‐threatening.</p> </li> <li> <p>Requires inpatient hospitalisation or prolongation of existing hospitalisation.</p> </li> <li> <p>Results in persistent or significant disability/incapacity.</p> </li> <li> <p>Is a congenital anomaly/birth defect.</p> </li> </ul> </p> <p>This is further explained in <a href="./appendices#CD006924-sec-0111">Appendix 1</a>, and AstraZeneca has confirmed that this definition was used in its included trials (even though this often was not made explicit in the paper reports). </p> <section id="CD006924-sec-0080"> <h6 class="title">Adults</h6> <p>We included 29 studies in the analysis (35,751 participants). Three studies compared low‐ and high‐dose formoterol plus ICS with a placebo treatment (<a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>). In the analysis, each treatment dose from the three studies was reported separately (resulting in 32 estimates of treatment effect). </p> <p>The number of adults experiencing one or more non‐fatal SAEs was very similar when formoterol was randomly assigned with ICS in comparison with ICS alone. One or more non‐fatal SAEs occurred in 401 out of 18,645 (2.1%) participants on regular formoterol with ICS and in 369 out of 17,106 (2.1%) participants on ICS alone. The Peto OR was 1.00 (95% CI 0.87 to 1.16; 29 studies; 35,751 participants; I<sup>2</sup> = 0%; <a href="#CD006924-fig-0004">Figure 4</a>; <a href="./references#CD006924-fig-0009" title="">Analysis 1.2</a>). For every 1000 adults treated for 26 weeks, 22 on ICS alone experienced an SAE; the corresponding risk for formoterol and ICS was also 22 (95% CI 19 to 25; <a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>). We assessed this evidence as of high certainty. The 95% CI for the absolute risk with formoterol and ICS indicates that, at most, three extra or three less adults per 1000 people may experience a non‐fatal SAE compared to ICS alone. </p> <div class="figure" id="CD006924-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events. </p> </div> </div> </div> </section> <section id="CD006924-sec-0081"> <h6 class="title">Children and adolescents</h6> <p>More children and adolescents randomised to formoterol and ICS reported non‐fatal SAEs, but the OR was not statistically significant. Non‐fatal SAEs were reported amongst 30 out of 2491 children and adolescents (1.2%) on regular formoterol and ICS compared to 13 out of 1544 (0.8%) children and adolescents randomised to ICS alone. </p> <p>The OR was 1.33 (95% CI 0.71 to 2.49; 10 studies; 4035 participants; ; I<sup>2</sup> = 5%; <a href="./references#CD006924-fig-0009" title="">Analysis 1.2</a>). For every 1000 children and adolescents treated for 12.5 weeks, 8 children experienced an SAE on ICS alone; the corresponding risk on formoterol and ICS was 11 children and adolescents (95% CI 6 to 21). We assessed this evidence as of moderate certainty because the 95% CI showed that there were up to 13 more, or two less children and adolescents on formoterol and ICS who may suffer an SAE in comparison with 8 per 1000 on ICS alone (<a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). </p> <p>The test for subgroup interaction between adults and children and adolescents did not find a significant impact of age on treatment effect during analysis as Peto OR (test for subgroup differences: Chi<sup>2</sup> = 0.72, df = 1, P = 0.40, I<sup>2</sup> = 0%; see <a href="#CD006924-fig-0004">Figure 4</a>; <a href="./references#CD006924-fig-0009" title="">Analysis 1.2</a>). </p> </section> </section> </section> <section id="CD006924-sec-0082"> <h4 class="title">Secondary outcomes</h4> <section id="CD006924-sec-0083"> <h5 class="title">Asthma‐related mortality</h5> <section id="CD006924-sec-0084"> <h6 class="title">Adults</h6> <p>Twenty‐eight studies involving 24,022 adults reported the number of asthma‐related deaths. One study did not report this outcome and was not included in the analysis (<a href="./references#CD006924-bbs2-0011" title="MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10µg twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids. World Allergy Organization Journal2012;5 (Suppl 2):S80‐1. MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:1203. MeltzerE , NolteH , LaforceC . Low‐dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology2009;A66:P92. MeltzerEO , KunaP , NolteH , NayakAS , LaforceC . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal2012;39(2):279‐89. [1399‐3003: (Electronic)] MeltzerEO , NolteH , LaForceC . Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice‐daily administered via a pressurized metered‐dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A5661. ">Meltzer 2012</a>). Three studies compared low‐ and high‐dose formoterol plus ICS with a placebo treatment (<a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>). In the analysis, each treatment dose from the three studies was reported separately (resulting in 31 estimates of treatment effect). </p> <p>Although it was not originally reported as an asthma‐related death in the trial report, one death in <a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> (OPTIMA) was subsequently attributed to status asthmaticus and septic shock in a subsequent meta‐analysis (<a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a>). The full report on the cause of death provided by the sponsors stated: "One of the deaths occurred in a 35 year old female after an 8 day hospitalisation for a severe asthma attack leading to intubation, ventilation, and nosocomial pneumonia with septic shock". Two deaths occurred in <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>, which were also attributed to asthma in the high‐dose budesonide/formoterol arm (<a href="#CD006924-fig-0005">Figure 5</a>; <a href="./references#CD006924-fig-0010" title="">Analysis 1.3</a>; <a href="#CD006924-tbl-0006">Table 4</a>). There were, therefore, three asthma‐related deaths in the formoterol and ICS treatment arm across all of the studies. We analysed the data using the pooled RD (as most studies had no deaths in either arm); the pooled RD was 0.0003 (95% CI −0.0007 to 0.0013; 28 studies; 24,022 participants; I<sup>2</sup> = 0%) at 26 weeks. This means that for every 1000 adults, there was a maximum of one more death potentially attributed to formoterol and ICS compared with ICS alone (<a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>). We assessed this evidence as of low certainty because there were only a total of three deaths due to asthma and because of imprecision. We were, therefore, unable to determine with certainty whether formoterol with ICS is as safe as regular ICS alone. </p> <div class="figure" id="CD006924-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.3 Asthma mortality." data-id="CD006924-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.3 Asthma mortality. </p> </div> </div> </div> </section> <section id="CD006924-sec-0085"> <h6 class="title">Children and adolescents</h6> <p>No asthma‐related deaths occurred amongst 4035 children and adolescents either on formoterol and ICS or ICS alone at 12.5 weeks. We analysed the data using the pooled RD, which was 0.0000 (95% CI −0.0034 to 0.0034) (<a href="#CD006924-fig-0005">Figure 5</a>; <a href="./references#CD006924-fig-0010" title="">Analysis 1.3</a>; <a href="#CD006924-tbl-0006">Table 4</a>). We assessed this evidence as of low certainty because there were no deaths from asthma in children and adolescents (<a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). </p> <p>The test for subgroup interaction between adults and children and adolescents did not find a significant impact of age on treatment effect during analysis as RD (test for subgroup differences: Chi<sup>2</sup> = 0.02, df = 1, P = 0.89, I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD006924-sec-0086"> <h5 class="title">Asthma‐related non‐fatal serious adverse events</h5> <section id="CD006924-sec-0087"> <h6 class="title">Adults</h6> <p>We included 27 studies involving 35,158 adults in the analysis. Two studies did not report this outcome and were not included in the analysis (<a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a>; <a href="./references#CD006924-bbs2-0011" title="MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10µg twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids. World Allergy Organization Journal2012;5 (Suppl 2):S80‐1. MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:1203. MeltzerE , NolteH , LaforceC . Low‐dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology2009;A66:P92. MeltzerEO , KunaP , NolteH , NayakAS , LaforceC . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal2012;39(2):279‐89. [1399‐3003: (Electronic)] MeltzerEO , NolteH , LaForceC . Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice‐daily administered via a pressurized metered‐dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A5661. ">Meltzer 2012</a>). Three studies compared low‐ and high‐dose formoterol plus ICS with a placebo treatment (<a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>; <a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>). In the analysis, each treatment dose from the three studies was reported separately (resulting in 30 estimates of treatment effect). </p> <p>The number of adults experiencing one or more asthma‐related non‐fatal SAEs was lower in participants randomised to receive formoterol and ICS compared to those receiving ICS alone. However, the difference was not statistically significant when analysed as either the Peto OR or the RD. A total of 90 out of 18,353 (0.49%) participants on regular formoterol and ICS and 102 out of 16,805 (0.6%) participants on ICS alone suffered an asthma‐related SAE. The Peto OR was 0.86 (95% CI 0.64 to 1.14; 27 studies; 35,158 participants; I<sup>2</sup> = 0%; <a href="#CD006924-fig-0006">Figure 6</a>; <a href="./references#CD006924-fig-0011" title="">Analysis 1.4</a>). This means that for every 1000 adults treated for 26 weeks, six experienced an asthma‐related non‐fatal SAE on ICS alone; the corresponding risk on formoterol and ICS was five adults (95% CI 4 to 7). We assessed this evidence as of moderate certainty due to the lack of independent assessment of causation of SAEs in most of the studies (see <a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a> and sensitivity analysis below). </p> <div class="figure" id="CD006924-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.4 Asthma‐related non‐fatal serious adverse events." data-id="CD006924-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.4 Asthma‐related non‐fatal serious adverse events. </p> </div> </div> </div> </section> <section id="CD006924-sec-0088"> <h6 class="title">Children and adolescents</h6> <p>In trials in participants who were younger than 18 years of age, the results were again more heterogeneous. Nine young people out of 2491 (0.36%) on regular formoterol and ICS and five out of 1544 (0.32%) on ICS alone suffered an asthma‐related SAE. The confidence interval around the increased odds of SAEs related to asthma was wide and not statistically significant (Peto OR 1.18, 95% CI 0.40 to 3.51; 10 studies; 4035 participants; I<sup>2</sup> = 59%; <a href="#CD006924-fig-0006">Figure 6</a>; <a href="./references#CD006924-fig-0011" title="">Analysis 1.4</a>). The pooled RD was 0.0006 (95% CI −0.0046 to 0.0057; <a href="#CD006924-tbl-0007">Table 5</a>; <a href="./references#CD006924-fig-0015" title="">Analysis 2.4</a>). There were three children and adolescents per 1000 on ICS alone with a serious adverse event related to asthma over 12.5 weeks, whilst we would expect four per 1000 on combination therapy (95% CI 1 to 11 per 1000). We assessed this evidence as of very low certainty because of the wide upper confidence interval of the absolute risk in the formoterol and ICS treatment arm; lack of independent assessment of causation of SAEs; and unexplained heterogeneity between trial results (<a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). </p> <p>The test for subgroup interaction between adults and children and adolescents did not find a significant impact of age on treatment effect during analysis as Peto OR (test for subgroup differences: Chi<sup>2</sup> = 0.32, df = 1, P = 0.57, I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD006924-sec-0089"> <h5 class="title">Other secondary outcomes</h5> <p>We did not identify data for other proposed secondary outcomes (e.g. respiratory‐related mortality, respiratory‐related non‐fatal SAEs, cardiovascular‐related mortality, cardiovascular‐related non‐fatal SAEs, or respiratory‐related non‐fatal life‐threatening events) either because it was not possible to obtain outcome data or the outcome was not measured in the study. </p> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> reported asthma‐related hospitalisations (defined as a stay of 24 hours or longer in a hospital, emergency department, or equivalent urgent care facility) in 39 out of 5868 adults on formoterol and ICS, and 32 out of 5861 adults on ICS alone at 26 weeks. The hazard ratio for the time to first serious asthma outcome on ICS and formoterol compared to ICS alone was 1.22 (95% CI 0.76 to 1.94). </p> <p>One intubation (ICS‐only group; <a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>) was reported. <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> reported no asthma‐related intubations at 26 weeks of ICS and formoterol or ICS alone. </p> </section> <section id="CD006924-sec-0090"> <h5 class="title">Sensitivity analyses</h5> <section id="CD006924-sec-0091"> <h6 class="title">Risk of bias</h6> <p>No deaths occurred in adults or children and adolescents in the unblinded studies (<a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0033" title="AstraZenecaSD‐039‐0719 . Long‐term safety of Symbicort in asthmatic children ‐ SAPLING [A six‐month, randomized, open‐label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=967 (first received 14 November 2008). BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. BergerWE , LefleinJG , GellerDE , ParasuramanB , MillerCJ , O'BrienCD , et al. The safety and clinical benefit of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings2010;31(1):26‐39. BergerWE , LefleinJG , UryniakT , O'BrienCD , O'DowdL . Long‐term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. LefleinJG , BergerWE , UryniakT , VervaetP , O'DowdL , O'BrienCD . Long‐term safety and systemic effects of budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S155. O'DowdL , BergerWE , LefleinJG , UryniakT , ParasuramanB , O'BrienCD . Health‐related quality of life (HRQL) and asthma control after long‐term treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152. ">SD‐039‐0719</a>), so exclusion of this study resulted in no difference in mortality outcomes. When these studies were excluded for non‐fatal SAEs, the Peto OR in adults did not change; however, in children and adolescents the Peto OR increased to 1.40 (95% CI 0.73 to 2.68, I<sup>2</sup> = 45%). A funnel plot did not suggest obvious asymmetry related to publication bias (<a href="#CD006924-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD006924-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events. </p> </div> </div> </div> <p>In adults, when we considered those studies with independent assessment of causation there was little difference in asthma mortality (RD 0.0003, 95% CI −0.0006 to 0.0012; 8 studies; 13,414 participants; I<sup>2</sup> = 0%) in comparison to the result from all studies (RD 0.0003, 95% CI −0.0007 to 0.0013; 28 studies; 24,022 participants ; I<sup>2</sup> = 0%) (<a href="./references#CD006924-fig-0016" title="">Analysis 3.1</a>). However, considering only the studies with independent outcome assessment moved the impact on non‐fatal asthma‐related SAEs towards the null (Peto OR 1.01, 95% CI 0.65 to 1.56; 7 studies; 13,191 participants; I<sup>2</sup> = 0%) compared to the result from all the studies (Peto OR 0.86, 95% CI 0.64 to 1.14; 27 studies; 35,158 participants; I<sup>2</sup> = 0%) (<a href="./references#CD006924-fig-0017" title="">Analysis 3.2</a>). </p> <p>There were not enough events in children and adolescents to carry out sensitivity analysis on detection bias for the asthma‐related outcomes. </p> </section> <section id="CD006924-sec-0092"> <h6 class="title">Restricting results to combined inhalers only</h6> <p>We considered the data for non‐fatal SAEs for sensitivity analysis by removing studies in which adults or children and adolescents were given separate inhalers. There were no great changes in results of the analysis in either adults or children and adolescents when compared to the full data set (<a href="#CD006924-tbl-0008">Table 6</a>). </p> <div class="table" id="CD006924-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis for asthma‐related non‐fatal serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Full data set</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Independent outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluding separate inhalers</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR (adults)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 0.86, 95% CI 0.64 to 1.14; participants = 35,158; studies = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 1.01, 95% CI 0.65 to 1.56; participants = 13,191; studies = 7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 0.94, 95% CI 0.69 to 1.28; participants = 30,679; studies = 30)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR (children)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 1.18, 95% CI 0.40 to 3.51; participants = 4035; studies = 10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 1.18, 95% CI 0.40 to 3.51; participants = 4035; studies = 10)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; OR: odds ratio.</p> </div> </div> </section> <section id="CD006924-sec-0093"> <h6 class="title">Methods of analysis</h6> <p>The analysis results were not sensitive to effect measure or choice of model. The primary outcomes were also analysed using Mantel‐Haenszel fixed‐effect and random‐effects models. The result of a fixed‐effect model for mortality was OR 1.17 (95% CI 0.60 to 2.29; <a href="./references#CD006924-fig-0018" title="">Analysis 4.1</a>). This method uses a correction for zero cells, which means that the pooled OR is smaller than the Peto OR, because the addition of 0.5 to all cells when the arms have similar numbers randomly assigned will generate an OR of 3 when only one event is reported. When outcomes are very sparse (as for mortality), the results are entirely dependent on the size of the zero cell adjustment and whether the treatment arms are balanced. </p> <p>For all‐cause SAEs in adults , the Mantel‐Haenszel fixed‐effect (OR 1.00, 95% CI 0.87 to 1.16) and random‐effects models (OR 0.99, 95% CI 0.86 to 1.14) yielded results identical to those obtained by the Peto method. As for asthma‐related SAEs in adults, the Mantel‐Haenszel fixed‐effect (OR 0.85, 95% CI 0.65 to 1.12) and random‐effects models (OR 0.88, 95% CI 0.66 to 1.16) provided results that were very similar to those obtained when the Peto model was used. Analyses were also carried out using the risk difference for following outcomes: all‐cause mortality, all‐cause non‐fatal SAEs, and asthma‐related non‐fatal SAEs (see <a href="#CD006924-tbl-0007">Table 5</a>). </p> </section> <section id="CD006924-sec-0094"> <h6 class="title">Dose of formoterol</h6> <p>The dose of formoterol used in all studies was within the licensed daily dose, so no sensitivity analysis was required to exclude unlicensed doses. </p> </section> </section> <section id="CD006924-sec-0095"> <h5 class="title">Subgroup analyses</h5> <p>The studies did not show a difference in all‐cause SAEs in adults between subgroups when they were classified according to the ICS type that was used (see  <a href="./references#CD006924-fig-0022" title="">Analysis 5.1</a>). This was the only outcome with sufficient data to justify subgroup analysis on the basis of ICS type and dose of budesonide. </p> <p>Although the results for adults and children and adolescents showed opposite directions of effect for non‐fatal SAEs (both all‐cause and asthma‐related), the confidence intervals were wide and the test for interaction did not show a significant interaction of treatment effect and age. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006924-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006924-sec-0096">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006924-sec-0155">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006924-sec-0096"></div> <section id="CD006924-sec-0097"> <h3 class="title" id="CD006924-sec-0097">Summary of main results</h3> <p>The CIs for all‐cause mortality in adults indicate that for every 1000 patients treated with regular formoterol and ICS in comparison with ICS alone, we can expect between one more and one less death in adults given formoterol in addition to ICS over an average of 26 weeks of treatment. The pooled Peto OR for adults was 1.25 (95% CI 0.61 to 2.56; moderate‐certainty evidence) and could not be calculated for children and adolescents because no deaths in this group were reported (low‐certainty evidence) (<a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). </p> <p>Regarding non‐fatal SAEs in adults, for every 1000 adults treated for 26 weeks, 22 on ICS alone experienced an SAE; the corresponding risk for formoterol and ICS was 22 adults (95% CI 19 to 25). The Peto OR was 1.00 (95% CI 0.87 to 1.16; high‐certainty evidence) (<a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In children and adolescents, for every 1000 children and adolescents treated for 12.5 weeks, 8 experienced an SAE on ICS alone; the corresponding risk on formoterol and ICS was 11 children and adolescents (95% CI 6 to 21; moderate‐certainty evidence) (<a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD006924-sec-0098"> <h3 class="title" id="CD006924-sec-0098">Overall completeness and applicability of evidence</h3> <p>The studies mainly recruited adults (mostly with FEV<sub>1</sub> &lt; 80% predicted) randomised to different licenced doses of formoterol and ICS for about 22 weeks (<a href="#CD006924-tbl-0003">Table 1</a>; <a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>). The smaller number of studies in children and adolescents (mostly with FEV<sub>1</sub> &lt; 80% predicted) up to 18 years were of shorter duration, with studies lasting up to 12 weeks (<a href="#CD006924-tbl-0003">Table 1</a>; <a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). </p> <p>With the addition of new studies resulting from the 2019 update search, the number of adults in this review has increased to 37,984, and the number of children and adolescents has increased to 4035. Uncertainty remains over the risks to children and adolescents of taking formoterol in addition to ICS, as there were either no events or the number of events for all outcomes was small. Regarding the adult data, overall there were more participants due to the inclusion of two large studies identified from the 2019 update (<a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>; <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>). The inclusion of the results from these two studies in this 2019 review update has resulted in better precision of the overall analyses. However, we were unable to conclude with high certainty that formoterol and ICS is as safe as taking ICS alone. </p> <p>Further investigation of the evidence in a funnel plot suggested that there was no publication bias that could have contributed to the uncertain result (<a href="#CD006924-fig-0007">Figure 7</a>). Three additional new adult trials were included in the review but not in the analyses as they did not report any data for outcomes investigated in this review (<a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>; <a href="./references#CD006924-bbs2-0030" title="SamsonMA , PanganibanSC . Effectiveness and safety of budesonide alone versus budesonide/formoterol in decreasing the number of severe exacerbations: a randomised controlled trial. Respirology2012;4:152. ">Samson 2012</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>). </p> <p>Most of the new trials were multicentre studies recruiting participants from the USA, South America, and Europe. One new trial was a single‐centre study recruiting participants in Japan (<a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>); two trials included in the 2012 update focused on African‐American adults (<a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a>; <a href="./references#CD006924-bbs2-0036" title="AstraZenecaD589BL00003 . Phase4/Symbicort® versus Pulmicort Flexhaler® in African Americans (Titan) [A 12‐week, randomized, double‐blind, double‐dummy, multi‐center, phase IV study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations twice daily versus budesonide inhalation powder DPI 180 μg × 2 inhalations twice daily, in adult and adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1614 (first received 1 June 2008). [D589BL00003] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Budesonide/formoterol pressurized metered‐dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. Journal of Asthma2012;49(1):70‐7. [1532‐4303: (Electronic)] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Effect of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(Suppl):5. SpectorSL , O'BrienCD , UryniakT , MartinUJ . Safety and tolerability of a budesonide/formoterol (BUD/FM) pressurized metered‐dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Chest2010;138(4):705A. ">Spector 2012</a>); and one trial studied Hispanic adults (<a href="./references#CD006924-bbs2-0041" title="NCT00419757 . An efficacy study comparing SYMBICORT® pressurised metered dose Iinhaler (pMDI) with budesonide hydrofluoroalkanes (HFA) pMDI, in hispanic subjects with ICS dependent asthma [A 12‐week, randomised, double blind, active‐controlled, multi‐centre, phase IIIB study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily versus budesonide HFA pMDI 160 mg x 2 actuations twice daily, in adult/adolescent (&gt; 12 Yrs) Hispanic subjects with asthma]. clinicaltrials.gov/ct2/show/NCT00419757 (first received 9 January 2007). [NCT00419757] ZangrilliJ , MansfieldLE , UryniakT , O'BrienCD . Efficacy of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide pressurized metered‐dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Annals of Allergy, Asthma and Immunology2011;107:258‐65. ">Zangrilli 2011</a>), so the diversity of ethnic groups represented is now greater. However, there remains very little in the way of separate data on adolescent participants recruited in any of the adult or adolescent trials. This is in spite of the fact that separate data on adolescents was to be reported in large trials initiated by the FDA (<a href="./references#CD006924-bbs2-0126" title="ChowdhuryBA , SeymourSM , LevensonMS . Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. New England Journal of Medicine2011;364(26):2473‐5. ">Chowdhury 2011</a>). </p> <section id="CD006924-sec-0099"> <h4 class="title">Certainty of the evidence</h4> <p>We assessed the risk of bias for all of the included studies (<a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). Almost all of the studies were double‐blind, and although allocation concealment was not well reported, it was likely to have been adequate, as all trials were sponsored or supported by product manufacturers. Lack of blinding of participants or care providers or outcome assessors was an issue in some studies, and these were downgraded accordingly. Because the trials were carried out for regulatory purposes, the collection of SAE data would have been assessed with the use of uniform definitions across studies. </p> <p>For asthma‐related events, we judged the risk of bias to be increased if studies did not undertake independent assessment of the causation of events, which may have introduced bias if the investigators had a high threshold for classifying events as asthma‐related. However, we would have expected such a bias to decrease any differences observed in asthma‐related events. </p> <p>The level of heterogeneity within the subgroup of paediatric trials was significant (I<sup>2</sup> = 59%) for asthma‐related non‐fatal SAEs, and could not be easily explained. Even with the addition of three studies from the 2019 update, it remains unclear whether taking formoterol was beneficial or harmful, as the CIs from two studies did not overlap (<a href="./references#CD006924-bbs2-0013" title="AstraZenecaSD‐039‐0682 . A 12‐week randomised, double‐blind, parallel‐group, multi‐centre phase‐III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1005 (first received 1 June 2002). MoriceAH , PetersonS , BeckmanO , KukovaZ . Efficacy and safety of a new pressurised metered‐dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics2008;21(1):152‐9. [1094‐5539: (Print)] ">Morice 2008</a>; <a href="./references#CD006924-bbs2-0038" title="AstraZenecaSD‐039‐0353 . Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid‐using asthmatic children. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1019 (first received 1 November 1998). TalA , SimonG , VermeulenJH . Symbicort® budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology2002;34(5):342‐50. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. European Respiratory Journal2001;18(Suppl 33):494s. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; 2001 April 1‐4; Prague. 2001:84‐5. TalA , SimonG , VermeulenJH , VitP , CobosN , EverardML , et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal2000;16(Suppl 31):384s. VermeulenJH , SimonG , TalA . Symbicort® budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4‐17 years. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D29. ">Tal 2002</a>), and the direction of effect from these two studies showed benefit, <a href="./references#CD006924-bbs2-0013" title="AstraZenecaSD‐039‐0682 . A 12‐week randomised, double‐blind, parallel‐group, multi‐centre phase‐III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1005 (first received 1 June 2002). MoriceAH , PetersonS , BeckmanO , KukovaZ . Efficacy and safety of a new pressurised metered‐dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics2008;21(1):152‐9. [1094‐5539: (Print)] ">Morice 2008</a>, and harm, <a href="./references#CD006924-bbs2-0038" title="AstraZenecaSD‐039‐0353 . Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid‐using asthmatic children. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1019 (first received 1 November 1998). TalA , SimonG , VermeulenJH . Symbicort® budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology2002;34(5):342‐50. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. European Respiratory Journal2001;18(Suppl 33):494s. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; 2001 April 1‐4; Prague. 2001:84‐5. TalA , SimonG , VermeulenJH , VitP , CobosN , EverardML , et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal2000;16(Suppl 31):384s. VermeulenJH , SimonG , TalA . Symbicort® budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4‐17 years. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D29. ">Tal 2002</a>. </p> <p>We rated the certainty of the evidence as high to low for adult evidence (<a href="./full#CD006924-tbl-0001">summary of findings Table for the main comparison</a>). For outcomes that were rated as moderate or low certainty, we downgraded by one point due to a wide upper confidence interval of the absolute risk, too few events in the ICS treatment arm, or lack of independent assessment of causation of SAEs. We rated the certainty of the evidence for outcomes reported in children and adolescents as moderate to very low (<a href="./full#CD006924-tbl-0002">summary of findings Table 2</a>). The evidence for all‐cause mortality was downgraded by two points due to no deaths and uncertainty of the treatment. Other outcomes were downgraded by one point due to wide confidence intervals, lack of independent assessment of causation of SAEs, or unexplained heterogeneity between trials. </p> </section> <section id="CD006924-sec-0100"> <h4 class="title">Addition of new trials</h4> <p>The 2019 update of this review included five new trials that examined the combination of formoterol and fluticasone in 1856 adults, <a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a>; <a href="./references#CD006924-bbs2-0016" title="NathanRA , D'UrzoA , BlazhkoV , KaiserK . Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine2012;12:67. [NCT00393991] ">Nathan 2012</a>; <a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a>; <a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a>, and 512 children (<a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a>). Although the number of participants in the included studies was sufficient, not enough events were observed to determine the safety of this combination compared to other combinations of ICS and formoterol in both children and adolescents and adults. Two new trials were also included that compared beclomethasone and formoterol in adults (<a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a>; <a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>). It was not possible to make any inferences regarding treatment with beclomethasone plus formoterol, as no events were observed in one trial (<a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a>), and one trial did not report safety outcomes in their publication (<a href="./references#CD006924-bbs2-0020" title="PaggiaroP , CorradiM , LatorreM , RaptisH , MuraroA , GessnerC , et al. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium‐high dose of inhaled corticosteroids. BMC Pulmonary Medicine2016;16(1):180. PaggiaroP , CorradiM , RaptisH , BaronioR , GessnerC , SiergiejkoZ , et al. High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium‐high dose of inhaled corticosteroids [Abstract]. European Respiratory Journal2014;44 (Suppl 58):P901. ">Paggiaro 2016</a>). We identified six new additional studies for the combination of budesonide and formoterol compared with budesonide alone in both adults and children (<a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a>; <a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a>; <a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a>; <a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a>; <a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a>; <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a>). Of the adult results, <a href="./references#CD006924-bbs2-0037" title="NCT01676987 . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma [Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial]. clinicaltrials.gov/ct2/show/NCT01676987 (first received 1 April 2009). PizzichiniMM , StirbulovR , FristcherCC , PizzichiniE . Efficacy and safety of a combination of budesonide/formoterol in a single capsule in uncontrolled asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2012;185:A3970. StirbulovR , FritscherCC , PizzichiniMMM . Evaluation of the efficacy and safety of a fixed‐dose, single‐capsule budesonide‐formoterol combination in uncontrolled asthma: a randomized, double‐blind, multicenter, controlled clinical trial. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia e Tisilogia2012;38(4):431‐7. ">Stirbulov 2012</a> was not included in the analysis because the outcomes were not reported in the publication. </p> <p>A large trial with 11,729 participants that was ongoing at the time of the 2012 update has now been included in the 2019 update for the comparison of combined formoterol and mometasone versus mometasone alone in adults (<a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>), however despite the addition of the new evidence, we were unable to determine with high certainty that ICS and formoterol are safe to use when compared to ICS alone. </p> </section> </section> <section id="CD006924-sec-0101"> <h3 class="title" id="CD006924-sec-0101">Potential biases in the review process</h3> <p>Selection of the best method to combine studies with rare events is contentious when event rates are low, not least because of the corrections required to calculate ORs with zero events (<a href="./references#CD006924-bbs2-0143" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. [0277‐6715: (Print)] ">Sweeting 2004</a>). It became apparent in the course of the review that the pooled ORs were heavily dependent on the zero adjustment used in the Mantel‐Haenszel and inverse variance methods, therefore we used the Peto OR and RDs to report the results of this review. The imbalance between trial arms is never greater than two to one, therefore the likely bias with use of the Peto OR is small (<a href="./references#CD006924-bbs2-0143" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. [0277‐6715: (Print)] ">Sweeting 2004</a>). </p> <p>Similarly, the included studies were influenced by the decision to restrict the review to trials that randomly assigned participants to formoterol plus ICS (i.e. excluding trials that randomised people to formoterol or placebo but who were taking background ICS). This decision reduces the risk of bias that can arise when participants discontinue their usual inhaled steroid medication if they feel better while receiving the randomly assigned treatment. This presupposes a similar risk of SAEs when formoterol and budesonide are delivered via a single inhaler, and when formoterol is introduced to ICS therapy via a separate inhaler, when both are randomly assigned treatments in a controlled trial. </p> </section> <section id="CD006924-sec-0102"> <h3 class="title" id="CD006924-sec-0102">Agreements and disagreements with other studies or reviews</h3> <section id="CD006924-sec-0103"> <h4 class="title">Mortality</h4> <p>More deaths reported in the Cochrane Review of trials comparing formoterol with placebo (<a href="./references#CD006924-bbs2-0123" title="CatesCJ , CatesMJ , LassersonTJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3; CD006923] ">Cates 2012</a>), and the present review comparing formoterol with ICS versus the same dose of ICS, occurred in participants who were randomly assigned to formoterol (with or without ICS; <a href="#CD006924-tbl-0006">Table 4</a>), although either result may have happened by chance. This is a cause for concern because although it may seem that many of the deaths were not related to asthma, it is often difficult to be sure of the exact cause of death, and the classification of cause of death is not straightforward. For example, the participant who died during the OPTIMA trial, <a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a>, was recorded by authors as dying from septic shock but was listed in <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> as dying from status asthmaticus and septic shock, whereas the 13‐year‐old boy who died in <a href="./references#CD006924-bbs2-0111" title="VonBergA , Papageorgiou SaxoniF , WilleS , CarrilloT , KattamisC , HelmsPJ . Efficacy and tolerability of formoterol Turbuhaler in children. International Journal of Clinical Practice2003;57(10):852‐6. ">Von Berg 2003</a> is listed in <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> as dying of respiratory failure, although the initial article reported that the cause of death was subarachnoid haemorrhage. <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> does not report all‐cause mortality in the subgroup of trials in participants receiving regular formoterol and maintenance ICS; the primary analysis on all‐cause mortality included the RELIEF study, which allowed regular LABA in both arms and was therefore not included in this review. The adjusted all‐cause mortality risk ratio in <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> is 1.79 (95% CI 0.80 to 4.00) when studies with any baseline ICS are considered; the conditional logistic regression was adjusted for trial effect (data on file provided by AstraZeneca). </p> <p>Only three asthma‐related deaths were reported in adults in this review, but the overview of <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> identified two additional asthma‐related deaths from the AstraZeneca database of trials in which participants were receiving maintenance ICS; all three deaths occurred in participants who had been randomly assigned to regular formoterol. </p> <p>Six additional deaths were reported when formoterol and ICS were compared with higher doses of ICS, three in each arm (<a href="./references#CD006924-bbs2-0135" title="JaeschkeR , O'ByrnePM , NairP , MejzaF , LeśniakW , BrozekJ , et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta‐analysis. Polskie Archiwum Medycyny Wewnetrznej2008;118(11):627‐35. ">Jaeschke 2008</a>). </p> <p>We have concluded that although the precision has become greater with addition of two large trials (<a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> and <a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a>), we agree with the conclusion of <a href="./references#CD006924-bbs2-0141" title="SearsMR , OttossonA , RadnerF , SuissaS . Long‐acting beta‐agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal2009;33(1):21‐32. [DOI: 10.1183/09031936.00145006] ">Sears 2009</a> that it is still insufficient to conclude that there is no increased mortality with formoterol use in conjunction with ICS. </p> </section> <section id="CD006924-sec-0104"> <h4 class="title">All‐cause non‐fatal serious adverse events</h4> <p>Information derived from trials in children and adolescents in this review is insufficient to permit a determination as to whether the increased risk of non‐fatal SAEs found with formoterol alone in <a href="./references#CD006924-bbs2-0123" title="CatesCJ , CatesMJ , LassersonTJ . Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3; CD006923] ">Cates 2012</a> (Peto OR 2.48, 95% CI 1.27 to 4.83) is abolished by the addition of ICS (Peto OR 1.33, 95% CI 0.71 to 2.49), as overlap in CIs leads to negative test findings for interaction (test for subgroup differences: Chi<sup>2</sup> = 8.41, df = 8, P = 0.39, I<sup>2</sup> = 5%) (<a href="#CD006924-fig-0004">Figure 4</a>). This is discussed more fully in the overview of the safety of regular formoterol or salmeterol in children (<a href="./references#CD006924-bbs2-0124" title="CatesCJ , OleszczukM , StovoldE , WielandLS . Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD010005.pub2] ">Cates 2012a</a>), and is in agreement with the findings of <a href="./references#CD006924-bbs2-0137" title="McMahonAW , LevensonMS , McEvoyBW , MosholderAD , MurphyD . Age and risks of FDA–approved long‐acting β2‐adrenergic receptor agonists. Pediatrics2011;128(5):e1147‐54. ">McMahon 2011</a>, who reported a significant association between younger age and increased risk of all‐cause non‐fatal SAEs with formoterol or salmeterol monotherapy, but no significant age association with combination inhalers. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006924-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD006924-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD006924-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.1 All‐cause mortality." data-id="CD006924-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.3 Asthma mortality." data-id="CD006924-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.3 Asthma mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.4 Asthma‐related non‐fatal serious adverse events." data-id="CD006924-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Formoterol and ICS versus same‐dose ICS, outcome: 1.4 Asthma‐related non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Formoterol and ICS versus same‐dose ICS (Peto OR), outcome: 1.2 All‐cause non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 1 All‐cause mortality." data-id="CD006924-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 2 All‐cause non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 3 Asthma mortality." data-id="CD006924-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 3 Asthma mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 4 Asthma‐related non‐fatal serious adverse events." data-id="CD006924-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference), Outcome 4 Asthma‐related non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 1 All‐cause mortality." data-id="CD006924-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 2 All‐cause non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 3 Asthma mortality." data-id="CD006924-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 3 Asthma mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 4 Asthma‐related non‐fatal serious adverse events." data-id="CD006924-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Formoterol and ICS versus same‐dose ICS (risk difference), Outcome 4 Asthma‐related non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis for adults: formoterol and ICS versus same‐dose ICS (risk difference, Peto OR), Outcome 1 Asthma mortality." data-id="CD006924-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis for adults: formoterol and ICS versus same‐dose ICS (risk difference, Peto OR), Outcome 1 Asthma mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis for adults: formoterol and ICS versus same‐dose ICS (risk difference, Peto OR), Outcome 2 Asthma‐related non‐fatal serious adverse events." data-id="CD006924-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis for adults: formoterol and ICS versus same‐dose ICS (risk difference, Peto OR), Outcome 2 Asthma‐related non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 1 All‐cause mortality." data-id="CD006924-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 1 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 2 All‐cause non‐fatal serious adverse events." data-id="CD006924-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 2 All‐cause non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 3 Asthma mortality." data-id="CD006924-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 3 Asthma mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 4 Asthma‐related non‐fatal serious adverse events." data-id="CD006924-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects), Outcome 4 Asthma‐related non‐fatal serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006924-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/urn:x-wiley:14651858:media:CD006924:CD006924-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_t/tCD006924-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Subgroup analysis for different LABA + ICS combinations, Outcome 1 All‐cause serious adverse events." data-id="CD006924-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Subgroup analysis for different LABA + ICS combinations, Outcome 1 All‐cause serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/media/CDSR/CD006924/image_n/nCD006924-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006924-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Regular formoterol and ICS compared to same‐dose ICS in adults with asthma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Formoterol and ICS compared to same‐dose ICS for chronic asthma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with chronic asthma<br/> <b>Intervention:</b> formoterol and ICS<br/> <b>Comparison:</b> same‐dose ICS </p> <p><b>Setting:</b> community; most were multicentre studies, of which 10 studies were conducted in the USA. Other multicentre studies were conducted in at least 2 to 27 countries including Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, Chile, Finland, France, Germany, Hungary, Ireland, Luxembourg, Mexico, Norway, the Philippines, Poland, Spain, Thailand, and the UK. 2 single‐centre studies were conducted in Japan and Russia. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with same‐dose ICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with formoterol and ICS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.25<br/> (0.61 to 2.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,751<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause non‐fatal serious adverse events</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/> (19 to 25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.87 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,751<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 3 more adults per 1000 experiencing an SAE compared to ICS treatment alone (i.e. 25 minus 22). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma mortality</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Pooled risk difference 0.0003 (−0.0007 to 0.0013)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24,022<br/> (31 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 3 deaths in the LABA + ICS treatment arm for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related non‐fatal serious adverse events</b> </p> <p>Follow‐up: 26 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (4 to 7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86<br/> (0.64 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,158<br/> (30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 1 more adults per 1000 experiencing an SAE compared to ICS treatment alone (i.e. 7 minus 6). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>ICS:</b> inhaled corticosteroids; <b>LABA:</b> long‐acting beta<sub>2</sub>‐agonist; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SAE:</b> serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the evidence for this outcome by 1 due to wide upper confidence interval of the absolute risk.<br/> <sup>2</sup>We downgraded the evidence for this outcome by 1 due to too few events in the ICS treatment arm.<br/> <sup>3</sup>We downgraded the evidence for this outcome by 1 due to lack of independent assessment of causation of SAEs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Regular formoterol and ICS compared to same‐dose ICS in adults with asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006924-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Regular formoterol and ICS compared to same‐dose ICS in children and adolescents with asthma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Formoterol and ICS compared to same‐dose ICS for chronic asthma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adolescents with chronic asthma<br/> <b>Intervention:</b> formoterol and ICS<br/> <b>Comparison:</b> same‐dose ICS </p> <p><b>Setting:</b> community; all were multicentre studies, with 4 studies conducted in the USA and 1 study in the UK. Other studies were conducted in at least 7 countries including Argentina, Australia, Belgium, Brazil, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, India, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Switzerland, and Ukraine. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with same‐dose ICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with formoterol and ICS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled risk difference 0.0000 (95% CI −0.0034 to 0.0034)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause non‐fatal serious adverse events</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (6 to 21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.33<br/> (0.71 to 2.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 13 more children and adolescents per 1000 experiencing an SAE compared to ICS alone (i.e. 21 minus 8). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related mortality</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No deaths</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pooled risk difference 0.0000 (95% CI −0.0034 to 0.0034)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Asthma‐related non‐fatal serious adverse events</b> </p> <p>Follow‐up: 12.5 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (1 to 11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.18<br/> (0.40 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4035<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The upper confidence interval of the absolute risk with formoterol and ICS resulted in 8 more children and adolescents per 1000 experiencing an SAE compared to ICS alone (i.e. 11 minus 3). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>ICS:</b> inhaled corticosteroids; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial; <b>SAE:</b> serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the evidence for this outcome by 2 due to no deaths and uncertainty of treatment.<br/> <sup>2</sup>We downgraded the evidence for this outcome by 1 due to wide confidence interval.<br/> <sup>3</sup>We downgraded the evidence for this outcome by 1 due to lack of independent assessment of causation of SAEs.<br/> <sup>4</sup>We downgraded the evidence for this outcome by 1 due to unexplained heterogeneity between trial results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Regular formoterol and ICS compared to same‐dose ICS in children and adolescents with asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006924-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adults daily metred dose and delivery of beclomethasone, budesonide, fluticasone, or mometasone with formoterol</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on formoterol/ICS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on ICS alone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose (µg), (steroid)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose formoterol (µg)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Once daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Twice daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combined inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Separate inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DPI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>pMDI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (weeks)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0003" title="ChuchalinA , StahlE , SvenssonK , OvcharenkoS , GoriachkinaL , SidorenkoI , et al. Formoterol (Oxis(r)) Turbuhaler(r) plus budesonide Turbuhaler(r) and budesonide alone improve health‐related quality of life vs non‐steroid therapy in mild to moderate asthma in Russia [Abstract]. American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A506. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN . Formoterol Oxis® Turbuhaler® plus budesonide Turbuhaler® is more effective than current non‐steroid therapy and budesonide alone in mild to moderate asthma in Russia. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ChuchalinAG , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , TsoiAN , EPOCH Study Group. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non‐corticosteroid therapy in Russia. International Journal of Clinical Practice2002; Vol. 56, issue 1:15‐20. ChuchalinAG , SvenssonK , StahlE , OvcharenkoSI , GoriachkinaLA , SidorenkoIV , et al. A health‐related quality‐of‐life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration2002;69(5):427‐33. ">Chuchalin 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0004" title="AstraZenecaSD‐039‐0716 . Efficacy of Symbicort versus its mono components ‐ SPRUCE 80/4.5 [A 12 week randomised, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (160/4.5mcg) versus its mono‐products (budesonide and formoterol) in children (at least 6 years of age) and adults with Asthma‐SPRUCE 80/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=970 (first received 1 August 2002). CorrenJ , KorenblatPE , MillerCJ , O'BrienCD , MezzanotteWS . Twelve‐week, randomised, placebo‐controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered‐dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics2007; Vol. 29, issue 5:823‐43. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in adults with mild to moderate persistent asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:928. MurphyK , NelsonH , ParasuramanB , BoggsR , MillerC , O'DowdL . The effect of budesonide and formoterol in one pressurized metered‐dose inhaler on patient‐reported outcomes in adults with mild‐to‐moderate persistent asthma. Current Medical Research and Opinion2008;24(3):879‐94. ">Corren 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0005" title="CorrenJ , MansfieldLE , PertsevaT , BlahzkoV , KaiserK . Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate‐to‐severe asthma. Respiratory Medicine2013;107(2):180‐95. ">Corren 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0006" title="AstraZenecaD58960001 . Gemini Symbicort pMDI [A randomized, double‐blind, active‐controlled, parallel‐group, single dummy, multicenter, 12 week study to assess the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations once‐daily (qd) compared to SYMBICORT pMDI 80/4.5 μg × 2 actuations qd, SYMBICORT pMDI80/4.5 μg × 2 actuations twice‐daily (bid) and to budesonide pMDI 160 μg × 2 actuations qd in asthmatic subjects 12 years of age and older]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1581 (first received 20 October 2003). KerwinEM , OppenheimerJJ , LaForceC , MillerCJ , O'DowdL , GoldmanM . Effects on pulmonary function of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152‐3. LaForceC , KerwinEM , OppenheimerJJ , MillerCJ , VervaetP , O'DowdL , et al. Safety of once‐daily (qd) budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S153. OppenheimerJJ , KerwinEM , LaForceC , MillerCJ , O'DowdL , GoldmanM . Asthma control with once‐daily (qd) budesonide/formoterol pressurized metered‐dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice‐daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. ">D5896C00001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0007" title="EudraCT2010‐020602‐14‐DE . Multinational clinical trial of 12 weeks of duration to test the efficacy and safety of a new drug called CHF 1535 200/6µg (fixed combination beclomethasone dipropionate/formoterol) versus beclomethasone dipropionate in adults asthmatic patients not adequately controlled on high doses of inhaled corticosteroids or on medium dose of inhaled corticosteroids plus long‐acting ß2 agonists. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2010‐020602‐14 (first received 23 April 2012). ">EudraCT 2010‐020602‐14‐DE</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BEC)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1600 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0009" title="AstraZenecaSD‐039‐0665 . Symbicort low dose once daily in mild to moderate asthmatic patients. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1013 (first received 1 November 1999). KunaP , ChuchalinA , RingdalN , De laPadillaEA , BlackP , LindqvistA , et al. Low‐dose single‐inhaler budesonide/formoterol administered once daily is effective in mild‐persistent asthma. European Respiratory Journal2001;18(Suppl 33):158s. KunaP , CreemersJ , VondraV , BlackPN , LindqvistA , NihlenU , et al. Once‐daily dosing with budesonide/formoterol compared with twice‐daily budesonide/formoterol and once‐daily budesonide in adults with mild to moderate asthma. Respiratory Medicine2006; Vol. 100, issue 12:2151‐9. ">Kuna 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>409</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0010" title="MatsunagaK , KawabataH , HiranoT , SugiuraH , MinakataY , IchinoseM . Difference in time‐course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulmonary Pharmacology and Therapeutics2013;26:189‐94. ">Matsunaga 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0011" title="MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10µg twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids. World Allergy Organization Journal2012;5 (Suppl 2):S80‐1. MeltzerE , NolteH , LaForceC . Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low‐dose inhaled corticosteroids [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:1203. MeltzerE , NolteH , LaforceC . Low‐dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology2009;A66:P92. MeltzerEO , KunaP , NolteH , NayakAS , LaforceC . Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal2012;39(2):279‐89. [1399‐3003: (Electronic)] MeltzerEO , NolteH , LaForceC . Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice‐daily administered via a pressurized metered‐dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181:A5661. ">Meltzer 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0012" title="AstraZeneca . A randomised, double‐blind, parallel‐group, multi centre phase‐III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 160/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 200 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/formoterol 160/4.5 mcg 2 inhalations b.i.d., delivered dose) in adolescents and adults with asthma. www.astrazenecaclinicaltrials.com/search/?itemId=8574676 (first received 26 November 2008). MoriceAH , HochmuthL , PutermanA , ArthedenL , BeckmanO . Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy and Clinical Immunology2005; Vol. 115, issue 2 Suppl:S3. MoriceAH , PetersonS , BeckmanO , OsmanlievD . Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice2007;61(11):1874‐83. [1368‐5031: (Print)] ">Morice 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>462</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0014" title="MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA . Therapeutic equivalence of budesonide/formoterol (BUD/FM) breath‐actuated inhaler (BAI) compared with BUD/FM pressurized metered‐dose inhaler (pMDI) in adults and adolescents with moderate to severe asthma. Journal of Allergy and Clinical Immunology2014;133 (Suppl 2):AB1. MurphyKR , DhandR , TrudoF , UryniakT , AggarwalA , EckerwallG . Therapeutic equivalence of budesonide/formoterol delivered via breath‐actuated inhaler vs pMDI. Respiratory Medicine2015;109(2):170‐9. ">Murphy 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12191</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0016" title="NathanRA , D'UrzoA , BlazhkoV , KaiserK . Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild‐to‐moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine2012;12:67. [NCT00393991] ">Nathan 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0018" title="AstraZenecaSD‐039‐0717 . A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐controlled trial of SYMBICORT® (160/4.5 mcg) versus its mono‐products (budesonide and formoterol) in adolescents (&gt; 12 years of age) and adults with asthma, international. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=969 (first received 1 July 2002). BakerJ , MartinP , ParasuramanB . Patient satisfaction with budesonide and formoterol in one pressurized metered‐dose inhaler in patients with asthma. Chest2007;132(4):509b. NoonanM , RosenwasserLJ , MartinP , O'BrienCD , O'DowdL . Efficacy and safety of budesonide and formoterol in one pressurised metered‐dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs2006;66(17):2235‐54. NoonanMJ , EidNS , UryniakT , O'BrienCD . Safety of once daily (qd) budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children and adolescents with asthma previously stable on twice daily (bid) BUD/FM pMDI [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:Abstract 711 [#K71]. RosenwasserLJ , NoonanMJ , MartinP , O'DowdL , O'BrienCD . Safety of budesonide and formoterol administered via one pressurized metered dose inhaler (budesonide/formoterol pMDI) in patients (&gt;12 years) with moderate to severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2007;119(1 Suppl):S5. Abstract 17. ">Noonan 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0022" title="PearlmanDS , LaForceC , KaiserK . Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone [Abstract]. European Respiratory Journal2011;55:727s. Abstract P3990. PearlmanDS , LaForceCF , KaiserK . Fluticasone/formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clinical Therapeutics2013;35(7):431‐7. ">Pearlman 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0024" title="PertsevaT , DissanayakeS , KaiserK . Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma [Abstract]. European Respiratory Journal2012;56:392s. Abstract P2191. PertsevaT , DissanayakeS , KaiserK . Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate‐to‐severe asthma: a randomised controlled trial. Current Medical Research and Opinion2013;29(10):1357‐69. ">Pertseva 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0025" title="AstraZenecaSD‐039‐0728 . Titratable dosing in moderate to severe asthmatics [A 52‐week, randomized, double‐blind, single‐dummy, parallel‐group, multicenter Phase III study comparing the long‐term safety of SYMBICORT® pMDI 160/4.5 mcg × 4 actuations twice daily to SYMBICORT® pMDI 160/4.5 mcg × 2 actuations twice daily and budesonide HFA pMDI 160 mcg × 4 actuations twice daily in adult and adolescent subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=964 (first received 1 August 2003). LawranceR , AmbroseH , GoldmanM . Effect of gly16arg beta2‐adrenergic receptor variation on the long‐term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered‐dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #420. O'BrienCD , PetersSP , PrennerBM , MartinP . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L57. O'BrienCD , PetersSP , PrennerBM , MartinP . Resource use with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L58. PetersSP , PrennerBM , MartinP , O'BrienCD . Long‐term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered‐dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #K5. PetersSP , PrennerBM , MezzanotteWS , MartinP , O'BrienCD . Long‐term safety and asthma control with budesonide/formoterol versus budesonide pressurised metered‐dose inhaler in asthma. Allergy and Asthma Proceedings2008;29:1‐18. PrennerBM , PetersSP , MartinP , O'BrienCD . Long‐term control of asthma symptoms with budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. Poster #L67. PrennerBM , PetersSP , MartinP , O'BrienCD . Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/FM) pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:#L66. TashkinD , ChippsB , BrownR , UryniakT , TrudoF . Responder analysis evaluating the long‐term treatment of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) in patients with moderate to severe asthma with versus without fixed airflow obstruction (FAO) [Abstract]. Chest2013;144:4. [DOI: 79A] ">Peters 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>443</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1600 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1645</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1646</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0029" title="PriceD , DutchmanD , MawsonA , BodaliaB , DugganS , ToddP . Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax2002;57(9):791‐8. [0040‐6376: (Print)] PriceMJ , BriggsAH . Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics2002;20(3):183‐94. PriceMJ , SondhiS , YanS , NythA , HouseK . Salmeterol/fluticasone propionate combination inhaler is more cost effective than fluticasone propionate in patients with asthma. European Respiratory Society 9th Annual Congress; 1999 Oct 9‐13; Madrid. 1999:#2459. ">Price 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0035" title="AstraZenecaSD‐039‐0726 . Efficacy of Symbicort pMDI administered once daily in adolescents and adults during 12 weeks ‐ STEM [A twelve‐week, randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma ‐ STEM]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=965 (first received 1 April 2003). ">SD‐039‐0726</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0036" title="AstraZenecaD589BL00003 . Phase4/Symbicort® versus Pulmicort Flexhaler® in African Americans (Titan) [A 12‐week, randomized, double‐blind, double‐dummy, multi‐center, phase IV study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations twice daily versus budesonide inhalation powder DPI 180 μg × 2 inhalations twice daily, in adult and adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1614 (first received 1 June 2008). [D589BL00003] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Budesonide/formoterol pressurized metered‐dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. Journal of Asthma2012;49(1):70‐7. [1532‐4303: (Electronic)] SpectorSL , MartinUJ , UryniakT , O'BrienCD . Effect of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(Suppl):5. SpectorSL , O'BrienCD , UryniakT , MartinUJ . Safety and tolerability of a budesonide/formoterol (BUD/FM) pressurized metered‐dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Chest2010;138(4):705A. ">Spector 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0039" title="NCT00381485 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED) [A 12‐week efficacy and safety study of two doses of mometasone furoate/formoterol combination formulation compared with mometasone furoate monotherapy, in persistent asthmatics previously treated with high‐dose inhaled glucocorticosteroids]. clinicaltrials.gov/ct2/show/NCT00381485 (first received 27 September 2006). [NCT00381485] NolteH , WhiteM , WeinsteinSF , NathanRA , GatesD , MeltzerEO . Evaluation of diary data on asthma control factors managed with combined mometasone furoate and formoterol fumarate in patients with severe asthma. Respirology2012;17 (Suppl 2):1‐16. WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB196. [0091‐6749] WeinsteinS , MurphyK , CorrenJ , NolteH , WhiteM . Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. European Respiratory Society https://www.ers‐education.org/home/browse‐all‐content.aspx?idParent=861112010;36(Suppl 54):5482. WeinsteinS , MurphyK , NolteH . Efficacy and safety of two doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. World Allergy Organization. 2012:S79‐80. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. WeinsteinS , MurphyK , WhiteM , NolteH , CorrenJ . Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered‐dose inhaler device. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5411. WeinsteinS , WhiteM , CorrenJ , NolteH . Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna. 2009:E280. WeinsteinSF , CorrenJ , MurphyK , NolteH , WhiteM . Twelve‐week efficacy and safety study of mometasone furoate/formoterol 200/10 [micro]g and 400/10 [micro]g combination treatments in patients with persistent asthma previously receiving high‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):280‐9. WeinsteinSF , WhiteM , CorrenJ , NolteH . Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered‐dose inhaler (MDI), in severe asthma patients previously treated with high‐dose inhaled corticosteroids (ICS). American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:J53. ">Weinstein 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5868</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5861</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 or 800 (MOM)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0041" title="NCT00419757 . An efficacy study comparing SYMBICORT® pressurised metered dose Iinhaler (pMDI) with budesonide hydrofluoroalkanes (HFA) pMDI, in hispanic subjects with ICS dependent asthma [A 12‐week, randomised, double blind, active‐controlled, multi‐centre, phase IIIB study comparing the efficacy and safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily versus budesonide HFA pMDI 160 mg x 2 actuations twice daily, in adult/adolescent (&gt; 12 Yrs) Hispanic subjects with asthma]. clinicaltrials.gov/ct2/show/NCT00419757 (first received 9 January 2007). [NCT00419757] ZangrilliJ , MansfieldLE , UryniakT , O'BrienCD . Efficacy of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide pressurized metered‐dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Annals of Allergy, Asthma and Immunology2011;107:258‐65. ">Zangrilli 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>Abbreviations: BEC: beclomethasone; BUD: budesonide; DPI: dry powder inhaler; FP: fluticasone propionate; ICS: inhaled corticosteroids; MOM: mometasone; pMDI: pressurised metered dose inhaler. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adults daily metred dose and delivery of beclomethasone, budesonide, fluticasone, or mometasone with formoterol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006924-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Children daily metred dose and delivery of beclomethasone, budesonide, fluticasone, or mometasone with formoterol</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on formoterol/ICS</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N on ICS alone</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose (µg), (steroid)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily metered dose formoterol (µg)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Once daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Twice daily</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Combined inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Separate inhalers</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DPI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>pMDI</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (weeks)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0013" title="AstraZenecaSD‐039‐0682 . A 12‐week randomised, double‐blind, parallel‐group, multi‐centre phase‐III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1005 (first received 1 June 2002). MoriceAH , PetersonS , BeckmanO , KukovaZ . Efficacy and safety of a new pressurised metered‐dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics2008;21(1):152‐9. [1094‐5539: (Print)] ">Morice 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>415</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0017" title='NCT01475032 . Efficacy study of the product "CHF 1535" versus beclomethasone (BDP) and free combo in asthmatic children. clinicaltrials.gov/show/NCT01475032 (first received 21 November 2011). '>NCT01475032</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>421</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BEC)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0023" title="PearlmanDS , EckerwallG , McLarenJ , LamarcaR , PuuM , GilbertI , et al. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6‐&lt;12 years). Annals of Allergy, Asthma and Immunology2017;118(4):489‐99. ">Pearlman 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0027" title="EudraCT2010‐024635‐16 . A double‐blind, double dummy, randomised, parallel group, multi‐centre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged 5 to less than 12 years with moderate to severe persistent reversible asthma. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 13/06/2016 (first received 03/05/2018). [EudraCT 2010‐024635‐16] NCT01511367 . Comparison of Flutiform, Fluticasone, and Seretide in treatment of moderate to severe asthma in paediatric patients. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2010‐024635‐16/results 18/01/2012 (first received 03/05/2018). [NCT01511367] PloszczukA , BoshevaM , SpoonerK , McIverT . Efficacy and safety of fluticasone propionate/formoterol fumarate in paediatric asthma patients: a randomised controlled trial. Therapeutic Advances in Respiratory Disease2018;12:1‐15. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. European Respiratory Journal2014;44(Suppl 58):P1167. PloszczukA , BoshevaM , SpoonerK , McIverT , DissanayakeS . Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma. Thorax2014;69 DBP(Suppl 2):A177. ">Ploszczuk 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (FP)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0028" title="AstraZenecaSD‐039‐0688 . Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 µg, 2 inhalations b.i.d.) compared to Pulmicort® (budesonide 100 mcg, 2 inhalations b.i.d.) and Pulmicort (budesonide 100 µg, 2 inhalations b.i.d.) plus Oxis® (formoterol 4.5 µg, 2 inhalations b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children: a double‐blind, double‐dummy, randomised, parallel‐group, phase III, multicentre 12‐week study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1003 (first received 1 March 2002). PohunekP , KunaP , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal2004;24(Suppl 48):379s. PohunekP , KunaP , JorupC , DeBoeckK . Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology2006; Vol. 17, issue 6:458‐65. PohunekP , MatulkaM , RybnicekO , KoprivaF , HonomichlovaH , SvobodovaT . Dose‐related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy and Immunology2004;15(1):32‐9. ">Pohunek 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0031" title="AstraZenecaSD‐039‐0714 . Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid‐using asthmatic adolescent patients: a double‐blind, double dummy, randomised, parallel group, phase III, multi‐centre study. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=999 (first received 14 November 2008). ">SD‐039‐0714</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 to 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0032" title="AstraZenecaSD‐039‐0718 . Symbicort in asthmatic children ‐ SEEDLING [A 12 week randomized, double‐blind, double‐dummy, placebo‐controlled trial of Symbicort TM (40/4.5 mcg) versus its mono‐products (budesonide and formoterol) in asthmatic children aged six to eleven years ‐ SEEDLING 40/4.5]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=968 (first received14 November 2008). PearlmanDS , MurphyKR , UryniakT , O'BrienCD , MezzanotteWS , DenverM . Safety of budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children with asthma previously treated with inhaled corticosteroids (ICSs) [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto#A710 (#K67). ">SD‐039‐0718</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0033" title="AstraZenecaSD‐039‐0719 . Long‐term safety of Symbicort in asthmatic children ‐ SAPLING [A six‐month, randomized, open‐label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=967 (first received 14 November 2008). BergerWE , BleeckerER , O'DowdL , MillerCJ , MezzanotteW . Efficacy and safety of budesonide/formoterol pressurized metered‐dose inhaler: randomized controlled trial comparing once‐ and twice‐daily dosing in patients with asthma. Allergy and Asthma Proceedings2010;31(1):49‐59. BergerWE , LefleinJG , GellerDE , ParasuramanB , MillerCJ , O'BrienCD , et al. The safety and clinical benefit of budesonide/formoterol pressurized metered‐dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings2010;31(1):26‐39. BergerWE , LefleinJG , UryniakT , O'BrienCD , O'DowdL . Long‐term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S8. LefleinJG , BergerWE , UryniakT , VervaetP , O'DowdL , O'BrienCD . Long‐term safety and systemic effects of budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S155. O'DowdL , BergerWE , LefleinJG , UryniakT , ParasuramanB , O'BrienCD . Health‐related quality of life (HRQL) and asthma control after long‐term treatment with budesonide and formoterol administered via one pressurized metered‐dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2 Suppl 1):S152. ">SD‐039‐0719</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0034" title="AstraZenecaSD‐039‐0725 . Efficacy of Symbicort pMDI administered once daily in children and adolescents during 12 weeks ‐ SPROUT [A twelve‐week, randomized, double‐blind, double‐dummy, active‐controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma ‐ SPROUT]. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=966 (first received 1 April 2003). EidNS , NoonanMJ , ChippsB , ParasuramanB , MillerCJ , O'BrienCD . Once‐ vs twice‐daily budesonide/formoterol in 6‐ to 15‐year‐old patients with stable asthma. Pediatrics2010;126(3):e565‐75. ">SD‐039‐0725</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0038" title="AstraZenecaSD‐039‐0353 . Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid‐using asthmatic children. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1019 (first received 1 November 1998). TalA , SimonG , VermeulenJH . Symbicort® budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology2002;34(5):342‐50. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Rapid and sustained improvements in lung function and symptom control with budesonide/formoterol in adolescent asthma. European Respiratory Journal2001;18(Suppl 33):494s. TalA , SimonG , VermeulenJH , PetruV , CobosN , EverardML , et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; 2001 April 1‐4; Prague. 2001:84‐5. TalA , SimonG , VermeulenJH , VitP , CobosN , EverardML , et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal2000;16(Suppl 31):384s. VermeulenJH , SimonG , TalA . Symbicort® budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4‐17 years. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D29. ">Tal 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 (BUD)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>Abbreviations: BEC: beclomethasone; BUD: budesonide; DPI: dry powder inhaler; FP: fluticasone propionate; ICS: inhaled corticosteroids; MOM: mometasone; pMDI: pressurised metered dose inhaler. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Children daily metred dose and delivery of beclomethasone, budesonide, fluticasone, or mometasone with formoterol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006924-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of pooled odds ratios</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Peto OR meta‐analysis: regular formoterol in addition to regular ICS versus ICS alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events F/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N F/ICS </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Peto OR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI start</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI end</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause non‐fatal serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peto OR 1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.51</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; ICS: inhaled corticosteroids; F: formoterol; N: number of participants; OR: odds ratio. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of pooled odds ratios</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006924-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mortality by cause of death</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment given</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cause of death (N)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0002" title="AstraZenecaSD‐039‐0666 . Symbicort high dose once daily in mild to moderate asthmatic patients. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1012 (first received 1 October 1999). BuhlR , CreemersJP , VondraV , MartelliNA , NayaIP , EkstromT . Once‐daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine2003;97(4):323‐30. [0954‐6111: (Print)] BuhlR , CreemersJPHM , VondraV , MartelliNA . Improved and maintained asthma control with once‐daily budesonide/formoterol single inhaler in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate‐persistent asthma. Thorax2001;56(Suppl 3):iii62. BuhlR , CreemersJPHM , VondraV , MartelliNA . Once‐daily budesonide/formoterol via a single inhaler is effective in mild‐to‐moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):21s. BuhlR , CreemersJPHM , VondraV , MartelliNA . Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001:D31. ">Buhl 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac arrest (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0019" title="BarnesPJ , O'ByrnePM , Rodriguez RoisinR , RunnerstromE , SandstromT , SvenssonK , et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax2000;55(Suppl 3):A4. GrosserD , SmithB . Low‐dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid‐treated patients. ACP Journal Club2002;137(1):19. JonssonB , BerggrenF , SvenssonK , O'ByrnePM . An economic evaluation of combination treatment with budesonide and formoterol in patients with mild‐to‐moderate persistent asthma. Respiratory Medicine2004;98(11):1146‐54. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide ‐ a cost‐effectiveness analysis. European Respiratory Journal2001;18(Suppl 33):517s. JönssonBG , BerggrenFE , SvenssonK , O'ByrnePM . Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal2001;18(Suppl 33):331s. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , RunnerstromEVA , SandstromT , SvenssonK , et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine2001;164(8):1392‐7. O'ByrnePM , BarnesPJ , Rodriguez‐RoisinR , SandtrömT , TattersfieldAE , RunnerströmEM , et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long‐term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal2001;18(Suppl 33):330s. ">O'Byrne 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (separate inhalers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Status asthmaticus, followed by septic shock (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0021" title="JuniperEF , SvenssonK , O'ByrnePM , BarnesPJ , BauerCA , LofdahlCGA , et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal1999;14(5):1038‐43. PauwelsR . Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy1998;53(42 Suppl):20‐3. PauwelsRA , LofdahlCG , PostmaDS , TattersfieldAE , O'ByrneP , BarnesPJ , et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine1997;337(20):1405‐11. [0028‐4793: (Print)] TattersfieldAE , PostmaDS , BarnesPJ , SvenssonK , BauerCA , O'ByrnePM , et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine1999;160(2):594‐9. ">Pauwels 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (separate inhalers)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0042" title="AstraZenecaSD‐039‐0349 . Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid‐using asthmatic adults. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1020 (first received 1 October 1998). BuhlR , ZetterstromO , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal2001;18(Suppl 33):48s. ZetterstromO , BuhlR , MellemH . Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; 2001 May 18‐23; San Francisco. 2001. ZetterstromO , BuhlR , MellemH , PerpinaM , HedmanJ , O'NeillS , et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal2001;18(2):262‐8. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3198. ZetterströmO , BuhlR , MellemH , PerpiñáM , HedmanJ , O'NeillS , et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal2000;16(Suppl 31):455s. Abstract P3199. ">Zetterstrom 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrovascular accident (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0001" title="AstraZenecaD5896C00022 . A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma [A 52‐week, randomised, double‐blind, parallel‐group, multi‐centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (≥12 years) African American subjects with asthma]. astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1588 (first received 8 February 2007). BrownRW , O'BrienCD , MarinUL , UryniakT , LamplKL . Long‐term cardiovascular safety, as evaluated by electrocardiographic monitoring, of budesonide/formoterol pressurized metered‐dose inhaler in African‐American patients with moderate to severe asthma [Abstract]. Journal of Allergy and Clinical Immunology2012;129(2 (Suppl 1)):AB76. BrownRW , O'BrienCD , MartinUJ , UryniakT , LamplKL . Long‐term safety and asthma control measures with a budesonide/formoterol pressurized metered‐dose inhaler in African American asthmatic patients: a randomised controlled trial. Journal of Allergy and Clinical Immunology2012;130(2):362‐7. [1097‐6825: (Electronic)] BrownRW , UryniakT , LamplKL . Long‐term safety of budesonide/formoterol pressurized metered‐dose inhaler (PMDI) and budesonide PMDI In African‐American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A1294. ">Brown 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Homicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0015" title="FDA . Clinical review of Dulera (NDA 22‐518). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM224593.pdf (accessed 3 October 2012). MurphyK , MeltzerE , WeinsteinS , NathanR , WhiteM , NolteH . Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Respirology2012;17(5):9‐9. MurphyKR , MeltzerEO , WeinsteinSF , NathanRA , WhiteM , GatesD , et al. Effects of mometasone furoate and formoterol fumarate combination therapy on 4 quality of life domains in patients with moderate asthma. Annals of Allergy, Asthma and Immunology2012;109 (Suppl 5):A55. NCT00383240 . Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). clinicaltrials.gov/ct2/show/NCT00383240 (first received 3 October 2006). NathanR , PearlmanD , NayakA , NolteH . Safety and tolerability of medium‐dose mometasone furoate/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium‐dose inhaled corticosteroids (alone or with long‐acting beta2‐agonist). Chest2009;136(4):8S. NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined medium‐dose mometasone furoate/formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB195. [0091‐6749] NathanR , PearlmanD , NolteH , NayakA . Efficacy and safety of combined mometasone furoate/formoterol 200/10 mcg in persistent asthmatics [Abstract]. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010:[E5489]. NathanR , PearlmanD , NolteH , NayakA . Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with medium‐dose inhaled corticosteroids (alone or with a long‐acting beta2‐agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009 Nov 5‐10; Miami. 2009. NathanRA , NolteH , PearlmanDS . Twenty‐six‐week efficacy and safety study of mometasone furoate/formoterol 200/10 μg combination treatment in patients with persistent asthma previously receiving medium‐dose inhaled corticosteroids. Allergy and Asthma Proceedings2010;31(4):269‐79. NathanRA , PearlmanD , NolteH , NayakA . Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice‐daily administered via a pressurized metered‐dose inhaler in subjects 12 years of age and older with moderate‐to‐severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine2010;181(Meeting Abstracts):A5412. NathanRA , WeinsteinSF , NolteH . Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metered‐dose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology2010;105(5 Suppl):A48‐9. ">Nathan 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and mometasone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uterine leiomyosarcoma (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0008" title="AstraZenecaSD‐039‐0689 . Efficacy and safety of Symbicort® (budesonide/formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid‐using asthmatic adolescents and adults: a double‐blind, double‐dummy, randomized, parallel group, phase III, multicentre study. https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=1002 (first received 1 July 2001). JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Efficacy and safety of high‐dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology2006; Vol. 11, issue 3:276‐86. JenkinsC , KolarikovaR , KunaP , CaillaudD , SanchisJ , PoppW , et al. Symbicort® Turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. Seattle, 2003:D034 Poster C37. ">Jenkins 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pulmonary embolus (but the death occurred after the control budesonide arm was discontinued so was not included in the meta‐analysis) (1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (low dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Road traffic accident (1), suicide (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol and budesonide (high dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute myocardial infarction (1), electric shock (1), asthma‐related death (2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide (low dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pancytopenia (1), cerebrovascular event (1), pneumonitis (1)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0026" title="NCT01444430 . A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents [A 26 week, randomized, double‐blind, parallel‐group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma‐related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2‐agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma]. clinicaltrials.gov/show/nct01444430 (first received 1 December 2011). PetersSP , BleeckerER , CanonicaGW , ParkYB , RamirezR , HollisS , et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. New England Journal of Medicine2016;375(9):850‐60. ">Peters 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Budesonide (high dose)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coronary artery insufficiency (1), myocardial ischaemia (1), death of unknown cause* (1), road traffic accident (1), cerebrovascular event (1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone and formoterol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1), cardiomyopathy (1), coronary artery thrombosis (1), chronic obstructive pulmonary disease (1), ischaemic stroke (1) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006924-bbs2-0040" title="NCT01471340 . A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241) (SPIRO) [A 26‐week randomized, double‐blinded, active controlled study comparing the safety of mometasone furoate/formoterol fumarate MDI fixed dose combination versus mometasone furoate MDI monotherapy in adolescents and adults with persistent asthma (protocol no. P06241 also known as P202)]. clinicaltrials.gov/ct2/show/NCT01471340 (first received 16 November 2011). WeinsteinCLJ , RyanN , ShekarT , GatesD , LaneSJ , AgacheI , et al. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology2019;143(4):1395‐1402. [DOI: 10.1016/j.jaci.2018.10.065] ">Weinstein 2019</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12+</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mometasone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Suicide (1), pulmonary embolism (1), gastrointestinal necrosis (1), pneumonia (1)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*The participant died at home suddenly, with no history of exacerbation or other adverse or serious adverse event, and without consulting a health practitioner. </p> <p>Abbreviations: N: number of participants.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Mortality by cause of death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006924-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of pooled risk differences</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Risk difference meta‐analysis: regular formoterol in addition to regular ICS versus ICS alone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events F/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N F/ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N events ICS </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total N ICS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI start</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CI end</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0034</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>All‐cause non‐fatal serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17,106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0031</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related mortality</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12,777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0013</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0034</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Asthma‐related serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18,353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16,805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.0046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0057</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; F: formoterol; ICS: inhaled corticosteroid; N: number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of pooled risk differences</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006924-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis for asthma‐related non‐fatal serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Full data set</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Independent outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Excluding separate inhalers</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR (adults)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 0.86, 95% CI 0.64 to 1.14; participants = 35,158; studies = 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 1.01, 95% CI 0.65 to 1.56; participants = 13,191; studies = 7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 0.94, 95% CI 0.69 to 1.28; participants = 30,679; studies = 30)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Peto OR (children)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 1.18, 95% CI 0.40 to 3.51; participants = 4035; studies = 10)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Peto OR 1.18, 95% CI 0.40 to 3.51; participants = 4035; studies = 10)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: CI: confidence interval; OR: odds ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis for asthma‐related non‐fatal serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/full#CD006924-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006924-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.61, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.61, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.71, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Asthma mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Asthma‐related non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.40, 3.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Formoterol and ICS versus same‐dose ICS (Peto OR, OR, risk difference)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006924-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Formoterol and ICS versus same‐dose ICS (risk difference)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Asthma mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Asthma‐related non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Formoterol and ICS versus same‐dose ICS (risk difference)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006924-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis for adults: formoterol and ICS versus same‐dose ICS (risk difference, Peto OR)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Asthma mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Independent outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No reported independent outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Asthma‐related non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Independent outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.65, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 No reported independent outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.52, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis for adults: formoterol and ICS versus same‐dose ICS (risk difference, Peto OR)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006924-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.60, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.60, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.87, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.71, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Asthma mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.00, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Asthma‐related non‐fatal serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Children and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.40, 3.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Formoterol and ICS versus same‐dose ICS (fixed‐effect versus random‐effects)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006924-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis for different LABA + ICS combinations</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.87, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 High‐dose budesonide in adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Moderate‐dose budesonide in adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.69, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Beclomethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Mometasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.20, 4.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis for different LABA + ICS combinations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006924.pub4/references#CD006924-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006924.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006924-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006924-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD006924-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD006924-note-0018">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006924-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006924-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006924-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006924\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006924\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006924\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006924\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006924\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006924.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006924.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006924.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006924.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006924.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728627885"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006924.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728627889"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006924.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec91b6b4df431',t:'MTc0MDcyODYyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 